UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 1997
OR
[ ] TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission file number 0-19612
IMCLONE SYSTEMS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 04-2834797
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
180 Varick Street,
New York, NY 10014
(Address of principal executive offices) (Zip Code)
(212) 645-1405
(Regristrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock, par
value $.001
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
The aggregate market value of voting and non-voting common equity held by
non-affiliates of the registrant as of March 27, 1998 was $178,172,328.
Indicate the number of shares outstanding of each of the registrant's
classes of common stock, as of the latest practicable date.
Class Outstanding as of March 27, 1998
----------------------------- ---------------------------------
Common Stock, par value $.001 24,327,685
Documents Incorporated by Reference: The registrant's definitive Proxy
Statement for the Annual Meeting of Stockholders scheduled to be held on May 27,
1998 to be filed with the Commission not later than 120 days after the close of
the registrant's fiscal year, has been incorporated by reference, in whole or in
part, into Part III, Items 10, 11, 12 and 13 of this Annual Report on Form 10-K.
IMCLONE SYSTEMS INCORPORATED
1997 Form 10-K Annual Report
TABLE OF CONTENTS
Page
PART I
Item 1. Business 1
Item 2. Properties 12
Item 3. Legal Proceedings 13
Item 4. Submission of Matters to a Vote of
Security Holders 13
PART II
Item 5. Market for the Registrant's Common Equity and
Related Stockholder Matters 13
Item 6. Selected Financial Data 14
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations 15
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 20
Item 8. Financial Statements and Supplementary Data 20
Item 9. Changes in and Disagreements With Accountants
on Accounting and Financial Disclosure 20
PART III
Item 10. Directors and Executive Officers of the Registrant 20
Item 11. Executive Compensation 20
Item 12. Security Ownership of Certain Beneficial Owners
and Management 20
Item 13. Certain Relationships and Related Transactions 20
PART IV
Item 14. Exhibits, Financial Statement Schedules and
Reports on Form 8-K 21
------------------------
Cautionary Factors With Respect to Forward-Looking Statements
Those statements contained herein that do not relate to historical information
are forward-looking statements. There can be no assurance that the future
results covered by such forward-looking statements will be achieved. Actual
results may differ materially due to the risks and uncertainties inherent in the
Company's business, including without limitation, the risks and uncertainties
associated with completing pre-clinical and clinical trials of the Company's
compounds that demonstrate such compounds' safety and effectiveness; obtaining
additional financing to support the Company's operations; obtaining and
maintaining regulatory approval for such compounds and complying with other
governmental regulations applicable to the Company's business; obtaining the raw
materials necessary in the development of such compounds; consummating
collaborative arrangements with corporate partners for product development;
achieving milestones under collaborative arrangements with corporate partners;
developing the capacity to manufacture, market and sell the Company's products,
either directly or with collaborative partners; developing market demand for and
acceptance of such products; competing effectively with other pharmaceutical and
biotechnological products; obtaining adequate reimbursement from third party
payors; attracting and retaining key personnel; protecting proprietary rights;
and those other factors set forth in "Management's Discussion and Analysis of
Financial Condition and Results of Operations--Overview and Risk Factors," all
as are further discussed herein.
(i)
PART I
Item 1. Business.
GENERAL
ImClone Systems Incorporated (the "Company" or "ImClone") is a
biopharmaceutical company engaged primarily in the research and development of
therapeutic products for the treatment of cancer and cancer-related disorders.
The Company's product candidates include interventional therapeutics for cancer
and cancer vaccines. The Company was incorporated in Delaware in 1984.
The Company's principal executive offices and laboratories are located at
180 Varick Street, New York, New York 10014 and the telephone number is (212)
645-1405.
DEVELOPMENT PROGRAMS
C225 Cancer Therapeutic. The Company's lead interventional therapeutic for
cancer is a chimerized (part mouse, part human) antibody that acts to block the
Epidermal Growth Factor receptor ("EGFr"). EGFr has been shown to be
over-expressed in the cells of approximately one-third of all solid cancers. It
is also expressed in select normal tissue. In vivo animal studies with human
tumors have shown that C225 in combination with various chemotherapeutic agents
(doxorubicin, cisplatin or paclitaxel) demonstrates a pronounced enhancement of
the anti-tumor effect of the chemotherapeutic agents, resulting in the
elimination of human tumors established in these animals. The studies have
demonstrated long-term tumor-free survival of animals. The Company's research
has also shown that C225 used alone has efficacy in renal cell carcinoma animal
models.
Since December 1994, the Company has initiated several Phase Ib/IIa
clinical trials of C225 at Memorial Hospital (the patient care arm of Memorial
Sloan-Kettering Cancer Center) ("Sloan-Kettering"), Yale Cancer Center,
University of Virginia, MD Anderson Cancer Center and the University of Alabama,
among others. These studies have involved intravenous administration of
escalating doses of C225, both with and without chemotherapeutic agents, in
patients with various solid cancers. Several of these studies are ongoing. These
studies have shown that the drug is generally well-tolerated. In 1997, the
Company initiated Phase Ib/IIa studies in head and neck cancer patients using
C225 alone (begun in July 1997), in conjunction with cisplatin (begun in April
1997) and in conjunction with radiation (begun in April 1997). Additionally, in
December 1997, the Company initiated a multi-center, open label Phase II
clinical trial to evaluate the effect of C225 on time to progression of disease
in 53 patients with metastatic renal cell carcinoma. ImClone expects to initiate
Phase II/III studies to evaluate the potential of C225 in various additional
tumor types, such as head and neck and pancreatic cancers.
BEC2 Cancer Vaccine. BEC2 is a monoclonal anti-idiotypic antibody which
the Company believes may be useful to prevent or delay the onset of recurrent
primary tumors or metastatic disease. The antibody, which mimics the ganglioside
GD3, has been tested since 1991 in Phase I clinical trials at Sloan-Kettering
against certain forms of cancer, including small cell lung carcinoma and
melanoma. BEC2 has shown prolonged survival of patients with small cell lung
carcinoma in a pilot study at Sloan-Kettering. The Company has granted Merck
KGaA, formerly E. Merck ("Merck"), a German-based pharmaceutical company, rights
to manufacture and market BEC2 worldwide, except that in North America, Merck
does not have the right to manufacture BEC2 and the Company has retained the
right to co-promote BEC2. It is the intent of the parties that ImClone will be
the bulk product manufacturer to support worldwide sales. In return, Merck is
paying ImClone research support, and is required to pay milestone fees and
royalties on future sales, if any, and will share revenues in North America. A
Phase III multinational clinical trial for BEC2 in treatment of limited disease
small cell lung carcinoma has been opened and patients are being screened for
treatment.
Chimerized Monoclonal Antibody Inhibitor of Angiogenesis. The Company has
developed a monoclonal antibody, c-p1C11, which is specific for the KDR receptor
for Vascular Endothelial Growth Factor ("VEGF"). The antibody is currently in
pre-clinical studies in preparation for the filing of an Investigational New
Drug ("IND") Application and the further testing of the product as a cancer
therapeutic. The Company is also preparing a humanized form of the antibody, in
conjunction with MRC Collaborative Centre. KDR and VEGF are known to be involved
in angiogenesis, which is the natural process of growth of new blood vessels. A
therapeutic product that would inhibit angiogenesis could be of value in
treatment of cancer as well as other diseases that depend on growth of blood
vessels, such as diabetic retinopathy, macular degeneration and rheumatoid
arthritis.
1
RESEARCH PROGRAMS
In addition to concentrating on its products in clinical development, the
Company performs ongoing research in a number of related areas.
Interventional Therapeutics
ImClone conducts an interventional cancer therapeutic research program in
the development of inhibitors of tyrosine kinase receptors (growth factor
receptors) associated with tumor cell regeneration and support.
In addition to its chimerized monoclonal antibody in development, the
Company is seeking to develop other antibodies that inhibit angiogenesis. In
connection with this research and development of the chimerized angiogenesis
inhibitor, the Company is sponsoring research programs at various academic
institutions to test KDR specific therapeutics in animal models.
The Company has also initiated a program to develop small molecule
antagonists of growth factor receptors, including both angiogenic growth factor
receptors and EGF receptors. In October 1997, the Company entered into an
agreement with CombiChem, Inc. ("CombiChem"), a combinatorial chemistry company,
pursuant to which the Company has access to CombiChem's library of small
molecules for screening in ImClone's assays for identification of lead
candidates. See "Corporate Collaborations and Out-licensing Arrangements -
CombiChem, Inc." The Company has also entered into an agreement with the
Institute for Molecular Medicine in Freiburg, Germany to screen small molecule
therapeutic candidates, including those provided by the compound libraries of
CombiChem, against various tyrosine receptors.
The Company is conducting research on the validation of vascular-specific
cadherin ("VE-cadherin") as a novel potential drug target to inhibit
cancer-associated angiogenesis. VE-cadherin is believed to play an important
role in angiogenesis by enabling the assembly of endothelial cells into vascular
tubes. Cancer growth is dependent on the formation of a capillary blood vessel
network in the tumor, and VE-cadherin antagonists may thus have utility as
anti-cancer agents. ImClone will test monoclonal antibodies against VE-cadherin
as potential angiogenesis inhibitors and use its high-throughput assays for the
identification of small molecule VE-cadherin inhibitors. In connection with this
program, the Company has also acquired exclusive rights to VE-cadherin-2 and to
antibodies to VE-cadherin and initiated a collaboration with Mario Negri
Institute for Pharmacological Research (Milan, Italy) to conduct pharmacological
research in the role of VE-cadherins in angiogenesis. See "Research
Collaborations and In-Licensing Arrangements - Mario Negri Institute for
Pharmacological Research." The National Cancer Institute (the "NCI") has awarded
to the Company a Phase I Small Business Innovation Research ("SBIR") grant of
approximately $100,000 to support its VE-cadherin program.
Cancer Vaccines
ImClone seeks to discover potential cancer vaccines as another route to
cancer treatment. Cancer vaccines would activate immune responses to tumors to
protect against local spread, distant metastases or recurrence of cancer.
Choosing appropriate cancer cell targets and generating effective immune
responses are the focus of ImClone's cancer vaccine program. For example,
research is being conducted on a possible malignant melanoma vaccine based on
the tumor associated antigen known as gp75. Patients with malignant melanoma are
known to produce antibodies and T cells that recognize gp75. Animal studies have
shown that a gp75 cancer vaccine is highly effective in eliciting an immune
response against melanoma cells and preventing growth of experimental melanoma
tumors in mice.
Endothelial Stem Cell Technology
The Company has proprietary technology capable of isolating endothelial
stem cells and is exploring uses of endothelial stem cells for stimulation of
collateral blood circulation in ischemias (e.g., myocardial ischemia and
peripheral vascular disease) as well as for gene therapy delivery. The Company
is considering whether to pursue this research directly or through its recently
established wholly-owned subsidiary, EndoClone Incorporated.
2
Hematopoiesis
The Company is conducting research in hematopoiesis (growth and
development of blood cell elements) aimed at discovering factors to support
hematopoietic stem cells and to control the proliferation, differentiation and
functional deterioration of hematopoietic elements.
The Company has an exclusive license from The National Institutes of
Health ("NIH") to the delta-like ("DLK") protein and gene for use in stem cell
and gene therapy. DLK is a member of a family of proteins which appear to have
the ability to maintain cells in an undifferentiated state.
The Company also has entered into a non-exclusive license and supply
agreement with Immunex Corporation ("Immunex") for use of the FLK-2/FLT-3 ligand
for ex vivo cell therapies. Immunex has taken a license from the Company to the
FLK-2 receptor, limited to the use by Immunex in the manufacture of the
FLK-2/FLT-3 ligand. Immunex is currently testing the ligand in human trials, for
stem cell mobilization, and for tumor inhibition.
The Company also has rights to a recombinant mutein form of Interleukin-6
("Interleukin-6m" or "IL-6m") which it has tested in human trials in cancer
patients to seek to stimulate platelet production. The Company is currently
monitoring third party research with IL-6m to explore the possibility that IL-6m
may be a critical factor in liver cell regeneration.
LICENSED DIAGNOSTICS AND INFECTIOUS DISEASE VACCINES
The Company has licensed its diagnostic and infectious disease vaccine
product areas, based on its earlier research, to corporate partners for further
development and commercialization. The Company has granted the Wyeth/Lederle
vaccine and pediatrics division of American Home Products Corporation ("American
Home") a worldwide license to manufacture and market its infectious disease
vaccines, which are in development. In January 1998, this agreement was extended
to allow the continuation through September 1999 of pre-clinical research in
preparation for clinical trials of infectious disease candidate vaccines for the
treatment of gonorrhea. ImClone receives annual funding under this agreement in
the amount of $300,000. The Company has also entered into a strategic alliance
with Abbott Laboratories ("Abbott") pursuant to which the Company has licensed
certain of its diagnostic products to Abbott on a worldwide basis. In mid-1995,
Abbott launched in Europe its first DNA-based test, using the Company's
proprietary Repair Chain Reaction ("RCR") DNA probe technology, for the
diagnosis of the sexually transmitted disease chlamydia. Abbott has added tests
for gonorrhea and mycobacteria, and has launched sales in the U.S. as well. In
June 1997, the Company received two milestone payments from Abbott totaling
$1,000,000 as a result of a patent issuance in Europe for the Company's RCR
technology. The issuance of the patent also entitles the Company to receive
royalty payments on sales in covered European countries for products using the
Company's RCR technology. Abbott will be entitled to deduct from royalties
otherwise due, 25% of such royalties due for a two-year period and 50%
thereafter until a total of $500,000 has been deducted. In December 1996, the
Company and Abbott modified this agreement to provide for an exclusive
sublicensing agreement with Chiron Diagnostics ("Chiron") for the Company's
patented DNA signal amplification technology, AMPLIPROBE. Under the terms of the
agreement all sales of Chiron branched DNA diagnostic probe technology in
countries covered by Company patents will be subject to a royalty to Abbott to
be passed through to the Company. For the year ended December 31, 1997, the
Company earned a total of $381,000 in royalty fees pursuant to its strategic
alliance with Abbott.
RESEARCH AND DEVELOPMENT
ImClone initiated its in-house research and development in 1986. The
Company has assembled a scientific staff with a variety of complementary skills
in a broad base of advanced research technologies, including oncology,
immunology, molecular and cell biology, antibody engineering, protein and
synthetic chemistry and high-throughput screening. The Company has also
recruited a staff of technical and professional employees to carry out
manufacturing of clinical trial materials at its Somerville, New Jersey
manufacturing facility. In addition to its research programs pursued in-house,
ImClone collaborates with certain academic institutions and corporations to
support research in areas of ImClone's product development efforts. The Company
has also entered into collaborations with major pharmaceutical companies in
order to obtain funding and product development and commercialization assistance
for certain of its therapeutic product candidates in exchange for specific
product licensing rights. The Company intends to enter into additional
agreements of this nature with appropriate pharmaceutical company partners with
the resources and experience to
3
assist the Company financially to successfully bring its products to market,
both in the U.S. and abroad. There can be no assurance, however, that the
Company will be successful in consummating any such arrangements.
The Company has recorded expenses of approximately $16,455,000,
$11,482,000, and $8,768,000 for research and development in the years ended
December 31, 1997, 1996 and 1995, respectively.
RESEARCH COLLABORATIONS AND IN-LICENSING ARRANGEMENTS
The Company's primary research collaborations which are non-clinical in
nature are the following.
CombiChem, Inc, San Diego, California. In October 1997, the Company
entered into a Collaborative Research and License Agreement with CombiChem, a
private company, to discover and develop novel small cell molecules for use
against selected targets for the treatment of cancer. The companies are
utilizing CombiChem's Discovery Engine and Universal Informer Library to
generate small molecules for screening in ImClone's assays for identification of
lead candidates. ImClone is providing CombiChem with research funding through
October 1999 in the amount of $500,000 annually (of which the first $500,000 was
paid in October 1997), milestone payments and royalties on marketed products
resulting from the collaboration, if any. Concurrently with the execution of the
Collaborative Research and License Agreement, the Company entered into a Stock
Purchase Agreement pursuant to which the Company purchased 250,000 shares of the
common stock of CombiChem, as adjusted, for aggregate consideration of
$2,000,000. CombiChem has agreed to use the proceeds from the sale of its stock
to ImClone for general corporate purposes.
Mario Negri Institute for Pharmacological Research, Milan, Italy. The
Company has a supported research agreement with Mario Negri Institute for
Pharmacological Research pursuant to which it supports the work of Dr.
Elisabetta Dejana who is investigating the role of a recently discovered protein
family, VE-cadherins, in angiogenesis. VE-cadherins are believed to enable the
formation of capillary blood vessels in solid tumors. In connection with the
commencement of this supported research program, the Company also acquired
proprietary rights to VE-cadherin-2 and to antibodies to VE-cadherin. The NCI
has awarded to the Company a Phase I SBIR grant in the amount of $100,000 to
support its VE-cadherin program.
Memorial Sloan-Kettering Cancer Center, New York, New York. The Company
has a supported research agreement with Sloan-Kettering to support research in
several areas, including potential cancer vaccine product, gp75. The Company has
an exclusive license from Sloan-Kettering to the gp75 tumor antigen and to the
BEC2 cancer vaccine and is required under the license to make good faith efforts
to proceed diligently with the manufacture and sale of these products.
Princeton University, Princeton, New Jersey. The Company has supported
research under the direction of certain faculty members at Princeton University.
The Company supported the research of Dr. Arnold Levine, Chairman of Princeton's
Department of Molecular Biology, in the area of the p53 tumor suppressor gene.
The Company has an exclusive license to the results of this research, which
license is terminable by the university if the Company does not meet certain
milestones in connection with the development of the licensed technology.
The Company has also funded research of Dr. Ihor Lemischka of Princeton
University on tyrosine kinase receptors, including FLK-2, antibodies and ligands
to such receptors, and hematopoietic stem cells. The Company has an exclusive
license from Princeton to the results of this research, which license is
terminable by the university if the Company does not meet certain developmental
milestones.
MRC Collaborative Centre, Mill Hill, United Kingdom. The Company is
funding research at the MRC Collaborative Centre on the humanization of its C225
and anti-KDR antibodies and in the expression of its C225 antibody in a
non-mouse cell line.
The University of North Carolina at Chapel Hill. The Company supports
research at The University of North Carolina at Chapel Hill in a number of
areas, including work of Dr. P. Frederick Sparling in connection with vaccine
candidates for N. gonorrhea and N. meningitidis, the results of which are
exclusively licensed to the Company. The Company also has exclusively licensed
from the university rights in connection with IL-6m.
The Company's primary in-licensing arrangements which have resulted in the
transfer of intellectual property rights to the Company are the following:
4
National Institutes of Health. In October 1996, the Company obtained an
exclusive, worldwide patent license from the NIH for the DLK protein and gene.
The agreement provides the Company with an exclusive license to stem cell and
gene therapy applications of the DLK protein and gene, as well as related
diagnostic uses.
Rhone-Poulenc Rorer. In June 1994, the Company obtained an exclusive
worldwide license from the pharmaceutical company, Rhone-Poulenc Rorer, Inc.
("Rhone-Poulenc Rorer") to pending patent applications covering the use of EGFr
monoclonal antibodies in combination with specific chemotherapeutic regimens.
The University of California at San Diego. In April 1993, the Company
obtained an exclusive worldwide license from the University of California to a
United States patent covering monoclonal antibodies that bind to EGFr. The
Company's C225 product is the chimerized form of one such antibody.
Generally, subject to earlier termination provisions contained in the
agreements, the licenses described above terminate upon the expiration of the
life of any patent or a related period on unpatented technology.
CLINICAL COLLABORATIONS
The Company's principal collaborations that are related to its clinical
trials are the following:
Memorial Sloan-Kettering Cancer Center. The Company has agreements with
Sloan-Kettering to support research in several areas, including the study of
potential cancer vaccine products BEC2 and gp75. The Company has an exclusive
license to the results of the research in the areas covered by the agreements.
The BEC2 antibody has been tested since 1991 in Phase I clinical trials at
Sloan-Kettering against certain forms of cancer, including small cell lung
carcinoma and melanoma.
The Company also has agreements with certain institutions by which such
institutions serve as sites for certain of the Company's clinical trials. For
example, for its C225 trials, the Company has entered into such agreements with
Yale Cancer Center, Sloan-Kettering, the University of Virginia, MD Anderson
Cancer Center and the University of Alabama, among others. For its BEC2 trials,
it is anticipated that numerous institutions in both the United States and
Europe will serve as clinical trial sites.
The European Organization for Research and Treatment of Cancer ("EORTC"),
an oncology research clinical group, is involved in the Phase III multi-national
clinical trial for BEC2 in the treatment of limited disease small cell lung
carcinoma, having responsibility for monitoring the trial in Europe at various
centers, as well as randomizing patients and managing data for the worldwide
study. It is anticipated that Quintiles, Inc., a contract research organization,
will serve as the Company's representative in coordinating and monitoring the
study in the United States.
The Company anticipates that arrangements similar to the above may be
employed for certain future Phase II/III studies for C225.
CORPORATE COLLABORATIONS AND OUT-LICENSING ARRANGEMENTS
To facilitate commercialization of certain of its products, ImClone has
entered into agreements with major pharmaceutical companies. Although the terms
of each agreement differ, these agreements generally provide for ImClone to
receive license fees, research funding and royalties on net sales of any future
products during the life of any relevant patent. In some cases, license fees
include payments related to the achievement of regulatory or product development
milestones.
Merck KGaA (Darmstadt, Germany)
The Company entered into a research and license agreement with Merck in
December 1990, which was subsequently amended, most recently in December 1997
(the "Amended License Agreement"). Under the Amended License Agreement, the
Company has granted Merck a license, with the right to sublicense, to
manufacture and market the Company's BEC2 product and its recombinant gp75
antigen, for all indications throughout the world; except that in North America
the Company has granted Merck a sole license, without the right to sublicense,
to market but not to manufacture BEC2. The Company retains the right to
co-promote BEC2 within North America. It is the intent of the parties that
ImClone will be the bulk product manufacturer to support worldwide sales. The
Company is required to give Merck the opportunity to negotiate a license in
North America to gp75 before granting such a license to any third party. The
Amended License Agreement requires Merck to make research support and
5
milestone payments to ImClone based on milestones achieved in the licensed
products' development, and to make royalty payments to ImClone on all sales of
the licensed products outside North America, if any, with a portion of the
earlier funding received by the Company under the agreement being creditable
against the amount of royalties due to the Company. The Amended License
Agreement provides for milestone payments of a total of $22,500,000 of which
$3,000,000 have been earned to date. Gross sales of BEC2 in North America will
be distributed in accordance with the terms of a co-promotion agreement for BEC2
to be negotiated by the parties. Pursuant to the Amended License Agreement,
conduct of the clinical trials and regulatory submissions outside North America
are the responsibility of Merck and within North America are the responsibility
of ImClone. Costs worldwide to conduct a multi-site, multi-national Phase III
clinical trial to obtain approval for the indication of the treatment of limited
disease small cell lung carcinoma for BEC2, including out-of-pocket costs of
ImClone (but not including costs of establishing a manufacturing facility) for
manufacturing materials for clinical trials, conduct of clinical trials and
regulatory submissions (other than drug approval fees which are the
responsibility of Merck or ImClone in their respective territories) are the
responsibility of Merck; provided, however, that should the expenses of such
clinical trial exceed 17 million Deutsche Marks, such excess expenses will be
shared 60% by Merck and 40% by ImClone. Costs for the conduct of additional
clinical trials for other indications shall be subject to separate budgets to be
negotiated by the parties. ImClone is responsible for providing the supply of
the active agent outside of North America at the expense of Merck, and it is the
intention of the parties that the cost of goods sold in North America be paid
out of gross sales of any licensed product in North America in accordance with a
co-promotion agreement to be negotiated.
The Amended License Agreement terminates upon the later of the last to
expire of any patents issued and covered by the technology or fifteen years from
the date of the first commercial sale, after which such license shall survive
without further royalty payment and is irrevocable. The Amended License
Agreement may be terminated earlier by ImClone in the event Merck fails to
pursue in a timely fashion regulatory approval or sale of a licensed product in
a country in which it has the right to do so. It also may be terminated earlier
by Merck if milestones are not achieved.
In the year ended December 31, 1997, the Company recorded $3,667,000 in
revenue from Merck under the Amended License Agreement, which is composed of
milestone and research and support payments.
In connection with the December 1997 amendment to the Amended License
Agreement, Merck purchased from the Company 400,000 shares of the Company's
Series A Convertible Preferred Stock (the "Series A Preferred Shares" or "Series
A Preferred Stock") for total consideration of $40,000,000, before issuance
costs of $3,000. The holders of the Series A Preferred Shares are entitled to
receive annual cumulative dividends of $6.00 per share. Dividends accrue as of
the issuance date of the Series A Preferred Shares and are payable on the
outstanding Series A Preferred Shares in cash on December 31 of each year
beginning December 31, 1999 or at the time of conversion or redemption of the
Series A Preferred Shares on which the dividend is to be paid, whichever is
sooner. Up to 100,000 Series A Preferred Shares are currently convertible into
the Company's common stock, $.001 par value (the "Common Stock") and an
additional 100,000 Series A Preferred Shares will become convertible on each of
January 1, 2000, January 1, 2001 and January 1, 2002. During the period from
issuance through December 31, 1999, the Series A Preferred Shares are
convertible at a price equal to $12.50 per share; during the period from January
1, 2000 through December 31, 2000 the Series A Preferred Shares are convertible
at a price equal to the average of the closing prices for the Common Stock for
the five trading days ending on December 31, 1999; during the period from
January 1, 2001 through December 31, 2001 the Series A Preferred Shares are
convertible at a price equal to the average of the closing prices for the Common
Stock for the five trading days ending on December 31, 2000; during the period
from January 1, 2002 through December 31, 2002 the Series A Preferred Shares are
convertible at a price equal to 88% of the average of the closing prices for the
Common Stock for the five trading days ending on December 31, 2001; and anytime
after January 1, 2003 the Series A Preferred Shares are convertible at a price
equal to the average of the closing prices for the Common Stock for the five
trading days ending on December 31, 2002. The conversion price is subject to
adjustment in the case of certain dilutive events. Further, in the event the
average market price of the Common Stock for the five consecutive trading days
ending one trading day prior to any trading day during which any Series A
Preferred Shares are outstanding exceeds 150% of the conversion price then in
effect, the Company has the right to require the holder of the Series A
Preferred Shares to convert all such shares that may be convertible. The Company
may also redeem in whole or any part of the Series A Preferred Shares then
outstanding at a redemption price of $120 per Preferred Share, plus accrued and
unpaid dividends thereon. In connection with the purchase of the Series A
Preferred Shares, Merck was granted certain registration rights with respect to
the shares of Common Stock underlying the Preferred Shares, and Merck agreed to
refrain from selling such shares of Common Stock for certain specified periods
of time. In accordance with the terms of the Series A Preferred Stock, the
holder is able to realize an assured incremental yield of $5,455,000 on the
conversion of the Series A Preferred Stock if
6
converted from January 1, 2002 through December 31, 2002. Such amount is being
amortized as a preferred stock dividend over a five-year period beginning with
the day of issuance. Accrued dividends on the Series A Preferred Stock were
$112,000 plus the incremental yield on the conversion discount of $51,000 at
December 31, 1997.
Abbott Laboratories
The Company entered into a research and license agreement with Abbott in
December 1992, which provides Abbott an exclusive worldwide license to
manufacture and distribute diagnostic products arising out of certain of
ImClone's research in diagnostics, including but not limited to ImClone's RCR
and Ampliprobe technologies for cancer detection and prognosis. This agreement
requires Abbott to exercise its best reasonable efforts to develop and
commercialize products incorporating RCR technology, failing which it can lose
its exclusive license to this technology. Abbott has the right on 30 days notice
to ImClone to terminate a product license in a particular country. In mid-1995,
Abbott launched in Europe its first DNA-based test, using the Company's RCR
technology, for the diagnosis of the sexually transmitted disease chlamydia.
Abbott has added tests for gonorrhea and mycobacteria, and has launched sales in
the U.S. as well. In December 1996, the Company and Abbott modified this
agreement to provide for an exclusive sublicensing agreement with Chiron for the
Company's patented DNA signal amplification technology, AMPLIPROBE. Under the
terms of the agreement all sales of Chiron branched DNA diagnostic probe
technology in countries covered by Company patents will be subject to a royalty
to Abbott to be passed through to the Company.
Under the agreement Abbott has paid ImClone up-front fees and research
support, and is obligated to pay milestone fees and royalties on sales. In June
1997, the Company received two milestone payments from Abbott totaling
$1,000,000 as a result of a patent issuance in Europe for the Company's RCR
technology, which is partially creditable against royalties as set forth below.
The issuance of the patent also entitles the Company to receive royalty payments
on sales in covered European countries for products using the Company's RCR
technology. Abbott will be entitled to deduct from royalties otherwise due, 25%
of such royalties due for a two-year period and 50% thereafter until a total of
$500,000 has been deducted. For the year ended December 31, 1997, the Company
earned a total of $381,000 in royalty fees pursuant to its strategic alliance
with Abbott. The agreement terminates upon the later of the last to expire of
any patents issued covered by the technology or, if no patents are granted,
twenty years, subject to certain earlier termination provisions contained in the
agreement.
American Home Products
In December 1987, the Company entered into a vaccine development and
licensing agreement with American Cyanamid Company ("Cyanamid") that provided
Cyanamid an exclusive worldwide license to manufacture and sell vaccines
developed during the research period of the agreement. In connection with the
agreement, Cyanamid purchased 410,001 shares of Common Stock of the Company.
During the three-year research period of the agreement, which period expired in
December 1990, the Company was engaged in the development of two vaccine
candidates, the first of which was for N. gonorrhea based on recombinant
proteins, and the second of which was for Herpes Simplex Virus based on
recombinant glycoproteins B and D.
In September 1993, the Company and Cyanamid, through its Lederle-Praxis
Biologicals division, entered into a research collaboration agreement which by
its terms supersedes the earlier agreement as to N. gonorrhea vaccine
candidates, but not as to Herpes Simplex Virus vaccine candidates. The successor
to Cyanamid, American Home, has the responsibility under this agreement to pay
research support to the Company, as well as milestone fees and royalties on
sales of any N. gonorrhea vaccine that might arise from the collaboration. In
January 1998, this agreement was extended to continue annual research funding
payable to ImClone in the amount of $300,000 through September 1999 and to
extend through such date the period by which American Home is required to have
initiated clinical trials with a vaccine candidate.
American Home has the responsibility under both agreements for conducting
pre-clinical and clinical trials of the vaccine candidates, obtaining regulatory
approval, and manufacturing and marketing the vaccines. There are penalties
payable by American Home in the event it fails to have filed for the
commencement of clinical trials by certain dates yet intends to continue to
develop the product, otherwise the product will revert to ImClone. American Home
is required to pay royalties to ImClone in connection with sales of the
vaccines.
In the year ended December 31, 1997, the Company recorded revenues of
$300,000 under the American Home agreements.
7
Immunex Corporation
In December 1996, the Company entered into technology cross-licensing
agreements with Immunex relating to FLK-2/FLT-3 ligand and its receptor. FLT-3
ligand is a hematopoietic growth factor. Under the terms of the agreements, the
Company has granted to Immunex an exclusive worldwide license to the receptor
for use in the manufacture of the ligand. In return, the Company will receive an
initial payment and a royalty based on the sales of the ligand by Immunex and
its sub-licensees, if any. In addition, Immunex has granted the Company a
non-exclusive license in the United States and Canada to use its patented
FLK-2/FLT-3 ligand, manufactured by Immunex, for ex-vivo stem cell expansion
together with an exclusive license to distribute the ligand with its own
proprietary products for ex-vivo expansion. Immunex has agreed to seek to obtain
the consent of its parent company, American Home, to expand the territory of
this license to include the world outside North America. Immunex will also
supply FLK-2/FLT-3 ligand to ImClone. The Company has been advised that Immunex
is conducting human clinical studies with FLK-2/FLT-3 ligand for stem cell
mobilization and for tumor inhibition. Subject to earlier termination provisions
contained in the agreements, ImClone's license terminates in December 2001,
subject to a five- year renewal period, and Immunex's license terminates
thirteen years after the first commercial sale of the product.
In the year ended December 31, 1997, the Company recorded no revenue from
Immunex under this agreement.
MANUFACTURING
For the Company to support its ongoing research and development it
maintains, supplies and staffs a facility for the preparation, analysis and
distribution of clinical supplies to various study centers. The Company operates
a clinical grade manufacturing facility for biologics in Somerville, New Jersey
that includes laboratories, storage areas, mechanical systems and qualified
staff for the production of and analysis of biological materials according to
the appropriate Federal, state and local regulations. At this facility, the
Company is currently producing C225, the EGFr antibody, to supply its clinical
trials, and packaging and distributing to clinical sites both the BEC2 antibody
and C225 antibody. This facility is operated according to current Good
Manufacturing Practices ("cGMP") which is a requirement for product manufactured
for use in clinical trials and for commercial sale. In January 1998, ImClone
completed the construction and commissioning of a new 1,750 square foot process
development center at this facility dedicated to manufacturing process
optimization for existing products and the pre-clinical and Phase I development
of new biological therapeutics.
ImClone has also established relationships with qualified contract vendors
to perform specialized testing and manufacturing operations not performed by
ImClone. The Company has in the past and expects to continue to establish
defined development and manufacturing arrangements with third party qualified
contract vendors to perform bulk and final product development and production to
support ImClone clinical program needs.
The materials that are used to manufacture the Company's products include
qualified cell lines developed by the Company and specially qualified raw
materials and components which the Company can obtain from a number of sources.
ImClone maintains necessary Quality Control and Quality Assurance oversights of
all materials used in the manufacture of the Company's clinical supplies.
Should any of the Company's products be approved for commercial sale, such
products will need to be manufactured in commercial quantities in compliance
with regulatory requirements and at acceptable costs. Although the Company has
developed products in the laboratory and in some cases has produced sufficient
quantities of materials for pre-clinical and clinical trials, production in
later stage clinical trials or commercial quantities may create technical
challenges for the Company. If the Company commercializes its products, the
Company may adapt its Somerville, New Jersey facility for use as its
commercial-scale manufacturing facility. To this end, the Company has taken
steps to complete a formal design concept for large scale manufacturing at this
facility. The Company is also evaluating the requirements of establishing a
separate commercial manufacturing facility at the Company's New Jersey location
or at some other location. The Company has limited experience in later stage
clinical-scale manufacturing and no experience in commercial-scale
manufacturing, and no assurance can be given that the Company will be able to
make the transition to later stage clinical or commercial production.
8
MARKETING
The Company does not have pharmaceutical marketing experience. If the
Company were to market its products itself or with a partner, significant
additional expenditures and management resources would be required to develop an
internal sales force and there can be no assurance that the Company would be
successful in penetrating the markets for any products developed or that
internal marketing capabilities would successfully be developed at all. The
Company has co-promotion rights for commercialization of its BEC2 cancer vaccine
product in North America pursuant to its Amended License Agreement with Merck,
and expects that, in other instances, it may enter into development agreements
with third parties that may include co-marketing or co-promotion arrangements.
In the alternative, the Company could grant exclusive marketing rights to its
corporate partners in return for up-front fees, milestone payments and royalties
on sales. Under these arrangements, the Company's partner may have the
responsibility for a significant portion of development of the product and
regulatory approval. In the event that the partner fails to develop a marketable
product or fails to market a product successfully, the Company's business may be
adversely affected.
PATENTS AND TRADE SECRETS
The Company seeks patent protection for its proprietary technology and
products, both in the United States and abroad. Patent applications have been
submitted and are pending in the United States, Canada, Europe and Japan as well
as other countries. The patent position of biopharmaceutical firms generally is
highly uncertain and involves complex legal and factual questions.
The Company currently is exclusive licensee or assignee of 39 issued
patents world-wide, 24 of which are issued United States patents. The Company
has the exclusive right to develop certain anti-EGFr receptor antibodies with
potential anti-tumor activity under a United States patent owned by the
University of California. Ten of the Company's U.S. patents are licensed from
Princeton University. Six of the Princeton patents relate to hematopoietic
receptor genes and the proteins they encode, such as the tyrosine kinase
receptors FLK-1 and FLK-2. The other four Princeton patents relate to a DNA
signal amplification system and p53 detection systems.
To date, the Company is the assignee or exclusive licensee of
approximately 35 families of United States and foreign patent applications. The
patent applications relate to a number of technologies including the use of EGFr
antibodies with chemotherapeutic agents; anti-idiotypic antibodies for treating
cancer, such as BEC2, antibodies to receptor tyrosine kinases, such as FLK-1 and
FLK-2; methods for amplifying and detecting DNA, such as the RCR technology; and
hematopoietic factors.
With respect to C225, the Company's EGFr cancer inhibiting antibody, the
Company is the exclusive licensee of an issued U.S. patent from the University
of California covering certain monoclonal antibodies that inhibit epidermal cell
growth. The Company is also the exclusive licensee from Rhone-Poulenc Rorer of a
family of patent applications seeking to cover antibodies to EGFr used in
conjunction with chemotherapeutic agents. The EGFr antibodies being developed by
the Company include chimerized monoclonal antibodies. Chimerized monoclonal
antibodies are the subject of patent applications and patents held by third
parties.
ImClone also has pending patent applications covering the chimeric and
humanized forms of the antibody and fragments thereof, in synergy with
anti-neoplastic agents, such as doxorubicin and cisplatin. Additionally,
humanized forms of the antibody and antibody fragments, are claimed, as well as
methods of inhibiting human tumors with C225 alone.
The Company's proprietary position with respect to its anti-tumor BEC2
monoclonal anti-idiotypic antibody is based on a patent application filed by
Sloan-Kettering and exclusively licensed to the Company. The Company is aware
that patents have been issued in the United States and Europe to a third party
covering anti-idiotypic antibodies and/or their use in the treatment of tumors.
With respect to the Company's research on inhibitors to angiogenesis based
on the FLK-1 receptor, the Company is the exclusive licensee of a family of
patents and patent applications covering the FLK-1 receptor and antibodies
thereto. The Company is also the assignee of a family of patent applications
filed by Company scientists covering angiogenesis-inhibiting antibodies to
receptors that bind VEGF. A specific patent application of such family claims
specifically the use of FLK-1 receptor antibodies to isolate cells expressing
the FLK-1 receptor on their cell surface. Additionally, the Company is a
co-owner of a recently filed patent application claiming the use of FLK-1
9
receptor antibodies to isolate endothelial progenitor cells that express FLK-1
on their cell surface. At present, the Company is seeking exclusive rights to
this invention from the co-owners.
The Company is also the exclusive licensee of a family of patent
applications covering novel cadherin molecules that are involved in endothelial
cell interactions; such interactions are believed to be involved in angiogenic
processes. The subject patent applications cover antibodies that bind to, and
affect, the cadherin molecules.
The United States Patent and Trademark Office has granted two patents for
the Company's cysteine-depleted IL-6 molecular variant, IL-6m, and the DNA that
encodes IL-6m. The patent and patent applications are co-owned by the Company
and the University of North Carolina, whose rights have been exclusively
licensed to the Company. The Company is aware of patents issued to a third party
in the United States and Europe covering cysteine depleted proteins. In
addition, the Company is aware of third-party patents for both recombinant and
native IL-6 and methods for its production. The Company is aware of a European
patent for the DNA encoding for human recombinant IL-6 and methods for its
production which has been exclusively licensed on a worldwide basis to a
pharmaceutical company. The Company has entered into a Settlement Agreement with
the pharmaceutical company whereby the pharmaceutical company has agreed to not
enforce its patent against the Company based on the Company's use of its IL-6m
patent or patent applications.
The Company's diagnostics program has been licensed for commercial
development to Abbott. The program includes target amplification and detection
methods, such as RCR technology, signal amplification methods, such as
AMPLIPROBE, and p53 mutation detection for assisting in cancer diagnosis. The
Company's proprietary position with respect to its diagnostics program is based
on numerous families of patents and patent applications, of which ImClone is
either the assignee or exclusive licensee. The Company currently is exclusive
licensee of an issued patent assigned to Princeton University related to the
underlying technology for its AMPLIPROBE DNA amplification and detection system.
The Company is aware that patent applications have been filed by, and that
patents have been issued to, third parties in the field of signal amplification
technology for DNA assays.
With respect to certain aspects of its technology, such as methods of
isolating and purifying antibodies and other proteins, collections of plasmids
in viable host systems, and antibodies that are specific for proteins that are
of interest to ImClone, the Company currently relies on, and intends to continue
to rely on, trade secrets, unpatented proprietary know-how and continuing
technological innovation to protect its competitive position. There can be no
assurance that others will not independently develop substantially equivalent
proprietary information or techniques.
Relationships between ImClone and its employees, scientific consultants
and collaborators provide these persons with access to ImClone's trade secrets,
know-how and technological innovation under confidentiality agreements with the
parties involved. Similarly, ImClone employees and consultants have entered into
agreements with ImClone which require that they do not disclose confidential
information of ImClone and that they assign to ImClone all rights to any
inventions made while in ImClone's employ relating to ImClone's activities.
GOVERNMENT REGULATION
The research and development, manufacture and marketing of human
pharmaceutical and diagnostic products are subject to regulation primarily by
the Food and Drug Administration ("FDA") in the United States and by comparable
authorities in other countries. These national agencies and other federal, state
and local entities regulate, among other things, research and development
activities and the testing, manufacturing, safety, handling, effectiveness,
labeling, storage, record keeping, approval, advertising and promotion of the
products that the Company is developing. Noncompliance with applicable
requirements can result in refusal to approve product license or other
applications, or revocation of approvals previously granted. Noncompliance also
can result in fines, criminal prosecution, recall or seizure of products, total
or partial suspension of production or refusal to allow the Company to enter
into supply contracts.
The process of obtaining requisite FDA approval has historically been
costly and time consuming. Current FDA requirements before a new human drug,
biological product or new diagnostic product (a medical device for which
efficacy must be proven) may be marketed in the United States include (i) the
successful conclusion of pre-clinical laboratory and animal tests, if
appropriate, to gain preliminary information on the product's safety, (ii)
filing with the FDA of an IND application to conduct human clinical trials for
drugs or biologics, (iii) the successful completion of adequate and
well-controlled human clinical investigations to establish the safety and
efficacy of the product for its recommended use and (iv) filing by a company and
approval by the FDA of a New Drug Application ("NDA") for a
10
drug product or a Biological License Application ("BLA") for a biological
product to allow commercial manufacturing of the drug or biologic.
Pre-clinical tests include laboratory evaluation of product chemistry and
animal studies to assess the potential safety and efficacy of the product and
its formulation. The results of the pre-clinical tests are submitted to the FDA
as part of an IND.
Clinical trials involve the administration of the product to patients
under the supervision of a qualified principal investigator. Such trials are
typically conducted in three sequential phases, although the phases may overlap.
In Phase I, the initial introduction of the drug into human subjects, the
product is tested for safety, dosage tolerance, absorption, metabolism,
distribution and excretion. Phase II involves studies in a limited patient
population to (i) determine the biological or clinical activity of the product
for specific, targeted indications, (ii) determine dosage tolerance and optimal
dosage, and (iii) identify possible adverse effects and safety risks. If Phase
II evaluations indicate that a product is effective and has an acceptable safety
profile, Phase III trials may be undertaken to further evaluate clinical
efficacy and to further test for safety within an expanded patient population at
multiple clinical study sites. The FDA reviews the results of the clinical
trials and may order the temporary or permanent discontinuation of clinical
trials at any time if it believes that clinical subjects are being exposed to an
unacceptable health risk. Investigational products used in both pre-clinical and
clinical tests must be produced in compliance with cGMP regulations pursuant to
FDA regulations.
In October 1988, the FDA issued new procedures designed to speed the
availability of new therapies to patients suffering from life-threatening
diseases such as AIDS and cancer. These procedures permit early consultation
with and commitment from the FDA regarding pre-clinical and clinical studies
necessary to gain market approval and to permit NDA's and BLA's to be approved
on the basis of expanded Phase II clinical data results.
Under current law, each domestic and foreign drug product manufacturing
establishment must be registered with, and determined to be adequate by, the FDA
before product approval. Domestic manufacturing establishments are subject to
inspections by the FDA for compliance with cGMP regulations and licensing
specifications after an NDA, BLA or PMA has been approved. Domestic and foreign
manufacturing facilities are subject to periodic FDA inspections and inspections
by the foreign regulatory authorities where applicable.
Sales outside the United States of products the Company develops also will
be subject to regulatory requirements governing human clinical trials and
marketing for drugs and biological products. The requirements vary widely from
country to country, but typically the registration and approval process takes
several years and requires significant resources. Products that have not been
approved by the FDA for sale in the United States may be exported for sale
outside of the United States only if they have been approved in any one of the
following countries: the European Union, Canada, Australia, New Zealand, Japan,
Israel, Switzerland and South Africa.
The Company's research and development programs involve the use of
biohazardous materials. Accordingly, the Company's business is subject to
regulations under federal, state and local laws regarding work force safety,
environmental protection and hazardous substance control, and to other present
and possible future federal, state and local regulations. The Company believes
that its safety procedures for handling hazardous materials comply with the
requirements of such laws and regulations.
The Company's ability to earn sufficient returns on its products may
depend in part on the extent to which reimbursement for the costs of such
products and related treatments will be available from government health
administration authorities, private health coverage insurers and other
organizations. Significant uncertainty exists as to the reimbursement status of
newly approved health care products, and there can be no assurance that adequate
third-party coverage will be available.
COMPETITION
Competition in the biopharmaceutical industry is intense and based
significantly on scientific and technological factors, the availability of
patent and other protection for technology and products, the ability to
commercialize technological developments and the ability to obtain governmental
approval for testing, manufacturing and marketing. The Company competes with
specialized biopharmaceutical firms in the United States, Europe and elsewhere,
as well as a growing number of large pharmaceutical companies that are applying
biotechnology to their operations. Many biopharmaceutical companies have focused
their development efforts in the human therapeutics area, including cancer, and
many major pharmaceutical companies have developed or acquired internal
biotechnology capabilities or made commercial arrangements with other
biopharmaceutical
11
companies. These companies, as well as academic institutions, governmental
agencies and private research organizations, also compete with the Company in
recruiting and retaining highly qualified scientific personnel and consultants.
The Company's ability to compete successfully with other companies in the
pharmaceutical field will also depend to a considerable degree on the continuing
availability of capital to the Company.
The Company is aware of certain products under development or manufactured
by competitors that are used for the prevention, diagnosis or treatment of
certain diseases the Company has targeted for product development. Various
companies are developing biopharmaceutical products that potentially directly
compete with the Company's product candidates, including in areas such as the
use of small molecules to EGFr or antibodies to those receptors to treat cancer,
the use of anti-idiotypic antibody or recombinant antigen approaches to cancer
vaccine therapy, the development of inhibitors to angiogenesis, and the use of
hematopoietic growth factors to treat blood system disorders to or for stem cell
or gene therapy. Some of these product candidates are in advanced stages of
clinical trials.
The Company's products under development and in clinical trials are
expected to address major markets within the cancer sector. The Company's
competition will be determined in part by the potential indications for which
the Company's compounds are developed and ultimately approved by regulatory
authorities. Additionally, the timing of market introduction of some of the
Company's potential products or of competitors' products may be an important
competitive factor. Accordingly, the relative speed with which the Company can
develop products, complete pre-clinical testing, clinical trials and approval
processes and supply commercial quantities to market are expected to be
important competitive factors. The Company expects that competition among
products approved for sale will be based on various factors, including product
efficacy, safety, reliability, availability, price and patent position.
HUMAN RESOURCES
ImClone initiated its in-house research and development in 1986. The
Company has assembled a scientific staff with a variety of complementary skills
in a broad base of advanced research technologies, including oncology,
immunology, molecular and cell biology, antibody engineering, protein and
synthetic chemistry and high-throughput screening. The Company has also
recruited a staff of technical and professional employees to carry out
manufacturing of clinical trial materials at its Somerville, New Jersey
facility. Of the Company's 110 full-time personnel on March 27, 1998, 44 were
employed in its product development, clinical and manufacturing programs, 39 in
research and 27 in administration. The Company's staff includes 15 persons with
Ph.D.s and 2 with M.D.s.
Item 2. Properties.
RESEARCH FACILITY--NEW YORK, NEW YORK
The Company currently occupies two contiguous leased floors at 180 Varick
Street in New York City, in which it is using approximately 30,000 of a total
available 40,000 square feet on the two floors. A portion of the lease expired
in 1993 and a portion expires in March 1999. The Company has extended the 1993
expired portion of the lease through March 1997 at 85% of each year's fair
market rental value and from 1997 to March 1999 at 100% of each year's fair
market rental value, for a portion of the premises. The rate for the remaining
portion of the premises is $264,000 annually through March 31, 1997 and $285,000
annually through March 31, 1999. Rent expense for the New York facility was
approximately $554,000, $508,000 and $493,000 for the years ended December 31,
1997, 1996 and 1995, respectively. The Company is currently in discussions
regarding the extension of the lease and considering other alternatives.
The acquisition, construction and installation of the Company's New York
research and development facilities were financed principally through the sale
of Industrial Development Revenue Bonds (the "IDA Bonds") issued by the New York
City Industrial Development Agency (the "NYIDA"). These facilities secure the
payment of debt service on the outstanding IDA Bonds.
MANUFACTURING FACILITY--SOMERVILLE, NEW JERSEY
In June 1992, the Company acquired certain property and a building in
Somerville, New Jersey at a cost to the Company of approximately $4,665,000,
including expenses. The Company has retrofitted the building to serve as its
clinical-grade manufacturing facility. When purchased, the facility had in place
various features, including
12
clean rooms, air handling, electricity and water for injection systems and
administrative offices. The cost for completion of facility modifications was
approximately $5,400,000.
Currently the facility is being operated to develop and manufacture
materials for the Company's clinical trials. Under certain circumstances, the
Company also may use the facility for the manufacturing of commercial products.
The timing and any additional costs of adapting the facility for commercial
manufacturing depend on several factors, including the progress of products
through clinical trials. In January 1998, ImClone completed the construction and
commissioning of a new 1,750 square foot process development center at this
facility dedicated to manufacturing process optimization for existing products
and the pre-clinical and Phase I development of new biological therapeutics. In
addition, the Company has taken steps to complete a formal design concept for
large scale manufacturing at this facility.
Item 3. Legal Proceedings.
There is no material legal proceeding pending against the Company or any
of its property, nor was any such proceeding terminated during the fourth
quarter of the year ended December 31, 1997.
Item 4. Submission of Matters to a Vote of Security Holders.
None.
PART II
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters.
MARKET INFORMATION
The Company's Common Stock is traded in the over-the-counter market and
prices are reported on the Nasdaq National Market tier of The Nasdaq Stock
Market under the symbol "IMCL".
The following table sets forth, for the periods indicated, the range of
high and low sale prices for the Common Stock on the Nasdaq National Market, as
reported by The Nasdaq Stock Market. The quotations shown represent inter-dealer
prices without adjustment for retail mark-ups, mark downs or commissions and may
not necessarily reflect actual transactions.
High Low
---- ---
Year ended December 31, 1997
First Quarter ............. $ 10 1/8 $ 5 3 /4
Second Quarter ............ $ 7 7/8 $ 4 5 /8
Third Quarter ............. $ 8 1/8 $ 4 5 /8
Fourth Quarter ............ $ 8 1/2 $ 5 21/32
High Low
---- ---
Year ended December 31, 1996
First Quarter ............. $ 9 3/8 $ 6
Second Quarter ............ $ 17 3/8 $ 7 1/4
Third Quarter ............. $ 9 7/8 $ 5 3/4
Fourth Quarter ............ $ 11 $ 6 7/8
STOCKHOLDERS
As of the close of business on March 27, 1998, there were approximately
195 holders of record of the Company's Common Stock. The Company estimates that
there are approximately 4,900 beneficial owners of its Common Stock.
13
DIVIDENDS
The Company has never declared cash dividends on its Common Stock and has
no present intention of declaring such cash dividends in the foreseeable future.
Pursuant to the terms of the Company's Series A Preferred Stock, the holders of
Series A Preferred Shares are entitled to receive cumulative dividends at the
annual rate of $6.00 per share, compounded annually, which dividends began to
accrue when the Series A Preferred Shares were issued on December 15, 1997.
Dividends on the outstanding Series A Preferred Shares are payable in cash on
December 31st of each year beginning on December 31, 1999, or at the time of
conversion, whichever is sooner. Series A Preferred Shares are of senior rank to
all shares of Common Stock with respect to payment of dividends.
RECENT SALES OF UNREGISTERED SECURITIES
In December 1997, the Company sold to Merck 400,000 Series A Preferred
Shares for total consideration of $40,000,000 pursuant to an exemption from
registration under Regulation D promulgated under the Securities Act of 1933, as
amended (the "Securities Act"). In March 1997, the Company issued 20,000 shares
of unregistered Common Stock to a single individual upon exercise of outstanding
warrants for aggregate consideration of $30,000. In March 1997, the Company
issued an aggregate of 190,000 shares of unregistered Common Stock jointly to
two individuals upon exercise of outstanding warrants for aggregate
consideration of $285,000. Such issuances were consummated as private sales
pursuant to Section 4(2) of the Securities Act.
Item 6. Selected Financial Data
Year Ended December 31,
--------------------------------------------------------
(In thousands, except per share data) 1997 1996 1995 1994 1993
---- ---- ---- ---- ----
Statements of Operations Data:
Revenues $ 5,348 $ 600 $ 800 $ 950 $ 5,403
Operating expenses:
Research and development 16,455 11,482 8,768 11,816 13,876
General and administrative 5,356 3,961 3,739 3,348 4,375
Interest and other income (1,523) (918) (3,120) (3,186) (573)
Interest and other expense 551 823 1,054 821 587
Equity in loss of affiliate -- -- -- 342 1,140
--------- --------- -------- -------- --------
Loss before extraordinary item (15,491) (14,748) (9,641) (12,191) (14,002)
Extraordinary loss on extinguishment of debt -- 1,267 -- -- --
--------- --------- -------- -------- --------
Net loss (15,491) (16,015) (9,641) (12,191) (14,002)
Preferred dividends (including incremental
yield of $51) 163 -- -- -- --
--------- --------- -------- -------- --------
Net loss to common stockholders $ (15,654) $ (16,015) $ (9,641) $(12,191) $(14,002)
========= ========= ======== ======== ========
Basic and diluted net loss per common share:
Loss before extraordinary item $ (0.67) $ (0.76) $ (0.72) $ (1.12) $ (1.58)
Extraordinary loss on extinguishment of debt -- 0.07 -- -- --
--------- --------- -------- -------- --------
Net loss $ (0.67) $ (0.83) $ (0.72) $ (1.12) $ (1.58)
========= ========= ======== ======== ========
Weighted average shares outstanding 23,457 19,371 13,311 10,903 8,879
(In thousands) 1997 1996 1995 1994 1993
---- ---- ---- ---- ----
Balance Sheet Data:
Cash and securities (1) $ 59,610 $ 13,514 $ 10,207 $ 3,032 $ 7,301
Working capital 56,671 7,695 3,735 (1,470) 1,215
Total assets 75,780 25,885 22,803 17,467 24,208
Long-term obligations 3,430 2,775 4,235 4,487 3,636
Accumulated deficit (117,464) (101,973) (85,958) (76,317) (64,126)
Stockholders' equity 68,226 16,589 11,823 8,176 14,812
14
(1) Includes $532,000 as of December 31, 1993 which was restricted for use only
for construction and equipping the Company's New York City facility under the
terms of certain industrial development bonds.
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
The following discussion and analysis by management is provided to
identify certain significant factors which affected the Company's financial
position and operating results during the periods included in the accompanying
financial statements.
OVERVIEW AND RISK FACTORS
The Company is a biopharmaceutical company engaged primarily in the
research and development of therapeutic products for the treatment of selected
cancers and cancer-related disorders. The products under development include
cancer therapeutics, cancer vaccines and inhibitors of angiogenesis. Since its
inception in April 1984, the Company has devoted substantially all of its
efforts and resources to research and development conducted on its own behalf
and through collaborations with corporate partners and academic research and
clinical institutions. The Company has generated a cumulative net loss of
approximately $117,464,000 for the period from its inception to December 31,
1997. The Company expects to incur significant additional operating losses over
each of the next several years. The major sources of the Company's working
capital have been the proceeds from the public and private sale of equity
securities, the sale of the IDA Bonds by the NYIDA (the proceeds of which have
been used for the acquisition, construction and installation of the Company's
research and development facility in New York City), license fees and contract
research and development fees and royalties from collaborative partners and
interest earned on these funds.
Substantially all of the Company's products are in various stages of
development, clinical studies or research. Substantially all the Company's
revenues were generated from license and research arrangements with
collaborative partners. The Company's revenues under its research and license
agreements with corporate sponsors have fluctuated and are expected to fluctuate
significantly from period to period. Similarly, the Company's results of
operations have fluctuated and are expected to fluctuate significantly from
period to period. These variations have been, and are expected to be, based
primarily on the timing of entering into supported research and license
agreements, the status of the Company's various products, the timing and level
of revenues from sales by its partner in diagnostics, Abbott, of products
bearing the Company's technology, the addition or termination of research
programs or funding support, performance by the Company's corporate
collaborators of their funding and marketing obligations, the achievement of
specified research or development milestones, including those relating to the
Company's Amended License Agreement with Merck, and variations in the level of
expenditures for the Company's proprietary products during any given period. The
Company's products will require substantial additional development and clinical
testing and investment prior to commercialization. To achieve profitable
operations, the Company, alone or with others, must successfully develop,
introduce and market its products. No assurance can be given that any of the
Company's product development efforts will be successfully completed, that
required regulatory approvals can be obtained or that any products, if
developed, will be successfully manufactured or marketed or achieve customer
acceptance.
RESULTS OF OPERATIONS
Years Ended December 31, 1997 and December 31, 1996
Revenues
Revenues for the years ended December 31, 1997 and 1996 were $5,348,000
and $600,000 respectively, an increase of $4,748,000. Revenue for the year ended
December 31, 1997 consisted of (i) $300,000 in research support from the
Company's partnership with American Home Products in infectious disease
vaccines, (ii) $2,000,000 in milestone payments and $1,667,000 in research and
support payments from the Company's Amended License Agreement with Merck, and
(iii) $1,000,000 in milestone payments and $381,000 in royalty revenue from the
Company's strategic alliance with Abbott in diagnostics. Revenues for the year
ended December 31, 1996 consisted of (i) $300,000 in research support from the
Company's partnership with the Wyeth/Lederle vaccine and pediatrics division of
American Home in infectious disease vaccines, (ii) $225,000 in royalty revenue
from the Abbott alliance, and (iii) $75,000 in license
15
fees from the Company's cross-licensing agreement with Immunex for novel
hematopoietic growth factors. Increased revenues for the year ended December 31,
1997 were primarily attributable to the Company's having achieved development
milestones under the Company's Amended License Agreement with Merck and the
Company's strategic license with Abbott.
Operating; Research and Development Expenses
Total operating expenses for the years ended December 31, 1997 and 1996
were $21,811,000 and $15,443,000, respectively, an increase of $6,368,000 or
41%. Research and development expenses for the years ended December 31, 1997 and
1996 were $16,455,000 and $11,482,000, respectively, an increase of $4,973,000
or 43%. Such amounts for the years ended December 31, 1997 and December 31, 1996
represented 75% and 74%, respectively, of total operating expenses. The increase
in research and development expenses for the year ended December 31, 1997 was
partly attributable to a one-time $2,233,000 non-cash compensation expense
recorded in connection with the extension of the term of an officer's warrant to
purchase 397,000 shares of Common Stock. The increase is also attributable to
costs associated with additional staffing, contract manufacturing and testing,
and expenditures in the functional areas of product development, manufacturing
and clinical and regulatory affairs to support the Company's lead therapeutic
product candidate, C225, as well as travel-related expenses to pursue strategic
partnerships for C225 and other product candidates. The remaining increase
reflects growth in the area of discovery research for future product candidates.
General and Administrative Expenses
General and administrative expenses include administrative personnel
costs, costs incurred in connection with pursuing arrangements with corporate
partners and technology licensors, and expenses associated with applying for
patent protection for the Company's technology and products. Such expenses for
the years ended December 31, 1997 and 1996 were $5,356,000 and $3,961,000,
respectively, an increase of $1,395,000 or 35%. The increase in general and
administrative expenses primarily reflects (i) $279,000 non-cash compensation
expense recorded in connection with an option grant to an officer of the Company
and (ii) additional support staffing for the expanding research, clinical,
development and manufacturing efforts of the Company, particularly with respect
to C225. The Company expects general and administrative expenses to increase in
future periods to support planned increases in research and development.
Interest and Other Income and Expenses
Interest and other income was $1,523,000 for the year ended December 31,
1997 compared to $918,000 for the year ended December 31, 1996, an increase of
$605,000 or 66%. The increase was primarily attributable to the increased
interest income earned from higher cash balances in the Company's investment
portfolio resulting from the proceeds received from a public offering of Common
Stock completed in March 1997 and a private placement of Series A Preferred
Stock completed in December 1997. Interest expense was $551,000 and $823,000 for
the years ended December 31, 1997 and 1996, respectively, a decrease of $272,000
or 33%. Interest expense for both periods primarily included interest on two
then outstanding IDA Bonds with an aggregate principal amount of $4,313,000
($2,113,000 of which was repaid in December 1997) and interest recorded on the
liability to Pharmacia and UpJohn Inc. ("Pharmacia"), for the reacquisition of
the worldwide rights to IL-6m as well as clinical material manufactured and
supplied by Pharmacia to the Company. The decrease was primarily attributable to
the May 1996 exchange of debt for Common Stock with the Oracle Group and a
Company Director.
Net Losses
The Company had net losses to common stockholders of $15,654,000 or $0.67
per share for the year ended December 31, 1997, compared with $16,015,000 or
$0.83 per share for the year ended December 31, 1996. The year ended December
31, 1996 included a $1,267,000 or $0.07 per share extraordinary loss on early
extinguishment of debt. This extraordinary loss resulted from the issuance of
Common Stock in lieu of cash repayment of a $2,500,000 loan due the Oracle Group
and a $180,000 long-term note owed to a Company Director. The decrease in the
16
per share net loss to common stockholders is due primarily to the increased
number of shares of Common Stock outstanding as a result of the March 1997
public offering of Common Stock.
Years Ended December 31, 1996 and December 31, 1995
Revenues
Revenues for the years ended December 31, 1996 and 1995 were $600,000 and
$800,000, respectively, a decrease of $200,000. Revenues for 1996 consisted of
(i) $300,000 in research support from the Company's corporate partnership with
the Wyeth/Lederle vaccine and pediatrics division of American Home, (ii) royalty
revenue of $225,000 from the Company's strategic alliance with Abbott, (iii) and
$75,000 in license fees from the Company's cross-licensing agreement with
Immunex. Revenues for 1995 consisted of (i) $300,000 in research support from
the Company's corporate partnership with the Wyeth/Lederle vaccine and
pediatrics division of American Home, and (ii) contract research fees of
$500,000 from the Company's strategic alliance with Abbott.
Operating; Research and Development Expenses
Total operating expenses for the years ended December 31, 1996 and
December 31, 1995 were $15,443,000 and $12,507,000, respectively, an increase of
$2,936,000 or 23%. Research and development expenses for the years ended
December 31, 1996 and December 31, 1995 were $11,482,000 and $8,768,000,
respectively, an increase of $2,714,000 or 31%. Such amounts for the years ended
December 31, 1996 and December 31, 1995 represented 74% and 70%, respectively,
of total operating expenses. The increase in research and development expenses
is primarily attributable to costs incurred for C225, the Company's lead
therapeutic product candidate. This includes additional staffing and
expenditures in the functional areas of product development, manufacturing and
clinical and regulatory affairs to support the manufacture of C225 for human
clinical trials and travel-related expenses to pursue strategic partnerships for
C225 (and other product candidates). The remaining increase reflects growth in
the area of discovery research for future product candidates.
General and Administrative Expenses
General and administrative expenses include administrative personnel
costs, costs incurred in connection with pursuing arrangements with corporate
partners and technology licensors, and expenses associated with applying for
patent protection for the Company's technology and products. Such expenses for
the year ended December 31, 1996 were $3,961,000 compared to $3,739,000 for the
year ended December 31, 1995, an increase of $222,000 or 6%. The increase
primarily reflects additional staffing to support the expanding research,
clinical, development and manufacturing efforts of the Company, particularly
with its lead therapeutic product candidate, C225. The Company expects general
and administrative expenses to increase in future years to support planned
increases in research and development.
Interest and Other Income and Expenses
Interest and other income was $918,000 for the year ended December 31,
1996 as compared to $3,120,000 for the year ended December 31, 1995, a decrease
of $2,202,000 or 71%. Other income for the year ended December 31, 1995 included
the Company's sale of the remaining one-half of its shares of capital stock of
Cadus Pharmaceutical Corporation, a company it assisted in founding in 1992, for
$3,000,000 to High River, LP. The greater interest income earned during the year
ended December 31, 1996 reflects the Company's improved cash position from the
November 1995 and February 1996 public sales of shares of its Common Stock.
Interest expense was $823,000 and $1,054,000 for the years ended December 31,
1996 and December 31, 1995, respectively, a decrease of $231,000 or 22%. Such
expense for both years primarily included interest on two then outstanding IDA
Bonds with an aggregate principal amount of $4,313,000 ($2,113,000 of which was
repaid in December 1997), interest recorded on the liability to Pharmacia for
the reacquisition of the worldwide rights to IL-6m and the contract manufacture
of clinical material, and interest accrued and the amortization of the non-cash
debt discount recorded in connection with the Company's August 1995 financing
with the Oracle Group.
17
Net Losses
The Company had net losses to common stockholders of $16,015,000 or $0.83
per share, and $9,641,000 or $0.72 per share, for the years ended December 31,
1996 and December 31, 1995, respectively. The net loss to common stockholders
for the year ended December 31, 1996 included a $1,267,000 or $0.07 per share
extraordinary loss on early extinguishment of debt through the May issuance of
Common Stock in lieu of cash repayment of a $2,500,000 loan due the Oracle Group
and a $180,000 long-term note owed to a Company Director.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1997, the Company's principal sources of liquidity
consisted of cash and cash equivalents and securities available for sale of
approximately $59,600,000. The Company has financed its operations since
inception primarily through the public and private sales of equity securities,
the sale of the IDA Bonds through the NYIDA, license fees and contract research
and development fees and royalties received under agreements with collaborative
partners and interest earned on these funds. Since inception, public and private
sales of equity securities have raised approximately $163,799,000 in net
proceeds, including approximately $23,200,000 raised in a public offering of
3,000,000 shares of Common Stock in March 1997 and approximately $39,997,000
raised in a private placement of 400,000 Series A Preferred Shares in December
1997. The sale of the IDA Bonds in each of 1985, 1986 and 1990 raised an
aggregate of $6,313,000, the proceeds of which have been used for the
acquisition, construction and installation of the Company's research and
development facility in New York City, and of which $2,200,000 is currently
outstanding. Since inception, the Company has earned approximately $28,662,000
from license fees, contract research and development fees and royalties from
collaborative partners, including approximately $5,348,000 received in 1997.
Since inception the Company has earned approximately $5,447,000 in interest
income, including approximately $1,523,000 in 1997.
The Company has obligations under various capital leases for certain
laboratory, office and computer equipment and also certain building improvements
primarily under a December 1996 financing agreement with Finova Technology
Finance, Inc. ("Finova"). The agreement allows the Company to finance the lease
of equipment and make certain building and leasehold improvements to existing
facilities involving amounts aggregating approximately $2,500,000. As of
December 31, 1997, the Company had entered into six individual leases
aggregating a total cost of $1,745,000. Each lease has a fair market value
purchase option at the expiration of a 42-month term. Pursuant to the agreement,
the Company issued to Finova a warrant expiring December 31, 1999 to purchase
23,220 shares of Common stock at an exercise price of $9.69 per share. The
Company recorded a non-cash debt discount of approximately $125,000 in
connection with this financing, which discount is being amortized over the
42-month term of the first lease. The financing agreement with Finova expired in
December 1997 and the Company did not utilize the full $2,500,000 under the
agreement. The Company anticipates that it will enter into a new financing
agreement with Finova during the second quarter of 1998 aggregating
approximately $2,000,000; however, no assurance can be given that such agreement
will be consummated.
The Company has expended and will continue to expend in the future
substantial funds to continue the research and development of its products,
conduct pre-clinical and clinical trials, establish clinical-scale and
commercial-scale manufacturing in its own facilities or in the facilities of
others, and market its products. The Company has entered into preliminary
discussions with several major pharmaceutical companies regarding various
alternatives concerning the funding of research and development for certain of
its products. No assurance can be given that the Company will be successful in
consummating any such alternatives. These discussions have included potential
significant strategic alliances for the development and commercialization of the
Company's lead product candidate, C225. Such strategic alliances could include
up-front license fees plus milestone fees and revenue sharing. There can be no
assurance that the Company will be successful in achieving such alliances, nor
can the Company predict the amount of funds which might be available to it if it
entered into such alliances or the time at which such funds would be made
available.
In January 1998, the Company completed the construction and commissioning
of a new 1,750 square foot process development center at its Somerville, New
Jersey facility at a cost of approximately $1,650,000. The Company has also
taken steps to complete a formal design concept for large scale manufacturing at
this facility. If the Company adapts this facility to large scale manufacturing
or does so at another location, it will incur substantial additional costs. The
lease on the Company's New York City facility expires in March 1999. The Company
is currently in discussions regarding the extension of the lease and is
considering other alternatives, such as relocating
18
its executive offices and laboratories to a new facility. Were the Company to
relocate its executive offices and laboratories, it would incur substantial
additional costs.
The IDA Bond issued in 1990 (the "1990 IDA Bond") in the outstanding
principal amount of $2,200,000 becomes due in 2004. If the lease on the
Company's New York City facility is terminated, the 1990 IDA Bond provides that
it will become due 60 days prior to such termination. Interest payable on the
1990 IDA Bond will aggregate approximately $250,000 during 1998. The Company has
granted the NYIDA a security interest in substantially all facility equipment
located in the New York facility to secure the obligations of the Company to the
NYIDA under the 1990 IDA Bond. In December 1997, the Company paid off the
outstanding principal on the IDA Bond issued in 1986 in the aggregate principal
amount of $2,113,000, plus accrued and unpaid interest thereon.
The holders of the Series A Preferred Shares are entitled to receive
cumulative dividends at an annual rate of $6.00 per share. Dividends accrue as
of the issuance date of the Series A Preferred Shares and are payable on the
outstanding Series A Preferred Shares in cash on December 31 of each year
beginning December 31, 1999 or at the time of conversion or redemption of the
Series A Preferred Shares on which the dividend is to be paid, whichever is
sooner. Accrued dividends were $112,000 plus the incremental yield on the
conversion discount of $51,000 at December 31, 1997.
Total capital expenditures made during the year ended December 31, 1997
were $2,981,000. Of the total capital expenditures made during the year ended
December 31, 1997, $1,324,000 has been reimbursed in accordance with the terms
of the Finova agreement discussed above which provides for improvements and
equipping of the Company's manufacturing facility in New Jersey. The balance of
capital additions was for equipment and computer-related purchases for both the
New Jersey facility and the corporate office and research laboratories in New
York.
The Company anticipates that its existing capital resources, including the
on-going research support of its corporate partners, should enable it to
maintain its current and planned operations through the end of the year 2000.
However, the receipt of such ongoing research support is subject to attaining
research and development milestones, certain of which have not yet been
achieved. There can be no assurance that the Company will achieve these
milestones. The Company's future working capital and capital requirements will
depend upon numerous factors, including the progress of the Company's research
and development programs, pre-clinical testing and clinical trials, the
Company's corporate partners fulfilling their obligations to the Company, the
timing and cost of seeking regulatory approvals, the cost of manufacturing
scale-up and effective commercialization activities and arrangements, the level
of resources that the Company devotes to the development of marketing and sales
capabilities, the costs involved in filing, prosecuting and enforcing patent
claims, technological advances, the status of competitors and the ability of the
Company to maintain existing and establish new collaborative arrangements with
other companies to provide funding to the Company to support these activities.
In order to fund its capital needs after the end of the year 2000, the Company
will require significant levels of additional capital and intends to raise the
capital through additional arrangements with corporate partners, equity or debt
financings or from other sources. There is no assurance the Company will be
successful in consummating any such arrangements. If adequate funds are not
available, the Company may be required to significantly curtail its planned
operations.
Uncertainties associated with the length and expense of pre-clinical and
clinical testing of any of the Company's products could greatly increase the
cost of development of such product and affect the timing of anticipated
revenues from product sales, and failure by the Company to obtain regulatory
approval for any product will preclude its commercialization. In addition, the
failure by the Company to obtain patent protection for its products may make
certain of its products commercially unattractive.
At December 31, 1997, the Company had net operating loss carryforwards for
federal income tax purposes of approximately $115,000,000 which expire at
various dates from 2000 through 2012. At December 31, 1997 the Company had
research credit carryforwards of approximately $2,303,000 which expire at
various dates between years 2001 and 2012. Pursuant to Section 382 of the
Internal Revenue Code of 1986, as amended, the annual utilization of the
Company's net operating loss and research credit carryforwards may be limited if
the Company experiences a change in ownership of more than 50 percentage points
within a three-year period. Since 1986, the Company experienced two ownership
changes. Accordingly, the Company is significantly limited in utilizing its tax
net operating loss carryforwards arising before such ownership changes to offset
future federal taxable income. Similarly, the Company is significantly
restricted in using its research credit carryforwards arising before such
ownership changes to offset future federal income tax expense.
19
OTHER ITEMS
The Company is evaluating the risks and costs associated with the year
2000 conversion. The Company intends to communicate with those organizations
with which it does business to ensure that year 2000 issues will be resolved in
a timely manner. If necessary modifications and conversions by those with which
the Company does business are not completed timely, the year 2000 conversion
issue may have a material adverse effect on the Company's consolidated financial
position and results of operations. Based on the Company's ongoing evaluation,
management does not currently believe that the costs to achieve year 2000
compliance will be material to the Company's financial position or results of
operations.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Not Applicable.
Item 8. Financial Statements and Supplementary Data.
The response to this item is submitted as a separate section of this
report commencing on Page F-1.
Item 9. Changes In and Disagreements With Accountants on Accounting and
Financial Disclosure.
Not Applicable.
PART III
The information required by "Item 10. - Directors and Executive Officers
of the Registrant"; "Item 11. - Executive Compensation"; "Item 12. - Security
Ownership of Certain Beneficial Owners and Management"; and "Item 13. - Certain
relationships and Related Transactions" is incorporated into Part III of this
Annual Report on Form 10-K by reference to the Company's Proxy Statement for the
Annual Meeting of Stockholders scheduled to be held on May 27, 1998.
20
PART IV
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K.
(a)(1)and(2). The response to this portion of Item 14. is submitted as a
separate section of this report commencing on page F-1. (a) (3)
Exhibits (numbered in accordance with Item 601 of Regulation S-K).
Incorporation
Exhibit No. Description by Reference
- ----------- ----------- ------------
3.1 Certificate of Incorporation, and all amendments
thereto N (3.1)
3.2 Amended and Restated By-Laws of the Company M (3.2)
4.1 Form of Warrant issued to the Company's officers
and directors under Warrant Agreements A (4.1)
4.2 Stock Purchase Agreement between Erbamont Inc. and
the Company, dated May 1, 1989 A (4.2)
4.3 Stock Purchase Agreement between American Cyanamid
Company (Cyanamid) and the Company dated December
18, 1987 A (4.3)
4.4 Form of Subscription Agreement entered into in
connection with September 1991 private placement A (4.4)
4.5 Form of Warrant issued in connection with
September 1991 private placement A(4.5)
4.6 Preferred Stock Purchase Agreement between the
Company and Merck KGaA ("Merck") dated December
3, 1997 P
4.7 Certificate of Designations, Preferences and
Rights of Series A Convertible Preferred Stock P
10.1 Company's 1986 Employee Incentive Stock Option
Plan, including form of Incentive Stock Option
Agreement F (10.1)
10.2 Company's 1986 Non-qualified Stock Option Plan,
including form of Non-qualified Stock Option
Agreement F (10.2)
10.3 Company's 401(k) Plan F (10.3)
10.4 Research and License Agreement between Merck and
the Company dated December 19, 1990 B (10.4)
10.5 Hematopoietic Growth Factors License Agreement
between Erbamont, N.V. and the Company, dated May
1, 1989, and Supplemental Amendatory Agreement
between Erbamont, N.V. and the Company dated
September 28, 1990 B (10.6)
10.6 Agreement between Cyanamid and the Company dated
December 18, 1987 and supplemental letter
agreement between Cyanamid and the Company dated
September 6, 1991 B (10.7)
10.7 Agreement between Hadasit Medical Research
Services & Development, Ltd. and the Company B (10.8)
10.8 Agreement between Hadasit Medical Research
Services & Development, Ltd. and the Company dated
September 21, 1989 B (10.9)
10.9 Supported Research Agreement between Memorial
Sloan-Kettering Cancer Center (MSKCC) and the
Company dated March 26, 1990 A (10.10)
10.10 License Agreement between MSKCC and the Company,
dated March 26, 1990 B (10.11)
10.11 License Agreement between MSKCC and the Company,
dated March 26, 1990 B (10.12)
10.12 License Agreement between MSKCC and the Company,
dated March 26, 1990 B (10.13)
10.13 Research Agreement between the Trustees of
Princeton University (Princeton) and the Company
dated January 1, 1991 B (10.14)
10.14 Research Agreement between Princeton and the
Company dated May 1, 1991 B (10.15)
10.15 Research Agreement between Princeton and the
Company dated May 1, 1991 B (10.16)
10.16 License Agreement between Princeton and the
Company dated March 20, 1991 B (10.17)
10.17 License Agreement between Princeton and the
Company dated May 29, 1991 B (10.18)
10.18 License Agreement between Princeton and Oncotech,
Inc. dated September 3, 1987 B (10.19)
10.19 Supported Research Agreement between The
University of North Carolina at Chapel Hill
("UNC") and the Company effective July 5, 1988 B (10.20)
10.20 License Agreement between UNC and the Company
dated July 5, 1988 B (10.21)
10.21 License Agreement between UNC and the Company
dated July 27, 1988 B (10.22)
10.22 Supported Research Agreement between UNC and the
Company effective April 1, 1989 B (10.23)
10.23 License Agreement between UNC and the Company
dated July 1, 1991 B (10.24)
10.24 Agreement between Celltech Limited and the Company
dated May 23, 1991 B (10.25)
10.25 Form of Non-disclosure and Discovery Agreement
between employees of the Company and the Company A (10.30)
10.26 Industrial Development Bond Documents: A (10.31)
10.26.1 Industrial Development Revenue Bonds (1985 ImClone
Systems Incorporated Project) A (10.31.1)
21
10.26.1.1 Lease Agreement, dated as of October 1, 1985,
between the New York City Industrial Development
Agency (NYCIDA) and the Company, as Lessee A (10.31.1.3)
10.26.1.2 Indenture of Trust, dated as of October 1, 1985,
between NYCIDA and United States Trust Company of
New York (US Trust), as Trustee A (10.31.1.2)
10.26.1.3 Company Sublease Agreement, dated as of October 1,
1985, between the Company and NYCIDA A (10.31.1.3)
10.26.1.4 Tax Regulatory Agreement, dated October 9, 1985,
from NYCIDA and the Company to US Trust, as
Trustee A (10.31.1.4)
10.26.1.5 Lessee Guaranty Agreement, dated as of October 1,
1985, between the Company and US Trust, as Trustee A (10.31.1.5)
10.26.1.6 First Supplemental Indenture of Trust, dated as of
November 1, 1985 from the NYCIDA to US Trust A (10.31.1.6)
10.26.1.7 Third Supplemental Indenture of Trust, dated as of
October 12, 1990 from NYCIDA to US Trust A (10.31.1.7)
10.26.2 Industrial Development Revenue Bonds (1986 ImClone
Systems Incorporated Project) A (10.31.2)
10.26.2.1 First Amendment to Company Sublease Agreement,
dated as of December 1, 1986, between the Company,
as Sublessor, and NYCIDA as Sublessee A (10.31.2.1)
10.26.2.2 First Amendment to Lease Agreement, dated as of
December 1, 1986, between NYCIDA and the Company,
as Lessee A (10.31.2.2)
10.26.2.3 Second Supplement Indenture of Trust, dated as of
December 1, 1986 between NYCIDA and US Trust, as
Trustee A (10.31.2.3)
10.26.2.4 Tax Regulatory Agreement, dated December 31, 1986,
from NYCIDA and the Company to US Trust, as
Trustee A (10.31.2.4)
10.26.2.5 First Amendment to Lessee Guaranty Agreement,
dated as of December 1, 1986, between the Company
and US Trust, as Trustee A (10.31.2.5)
10.26.2.6 Bond Purchase Agreement, dated as of December 31,
1986, between NYCIDA and New York Muni Fund, Inc.,
as Purchaser A(10.31.2.6)
10.26.2.7 Letter of Representation and Indemnity Agreement,
dated as of December 31, 1986, from the Company to
NYCIDA and New York Muni Fund, Inc., as Purchaser A(10.31.2.7)
10.26.3 Industrial Development Revenue Bonds (1990 ImClone
Systems Incorporated Project) A(10.31.3)
10.26.3.1 Lease Agreement, dated as of August 1, 1990,
between NYCIDA and the Company, as lessee A(10.31.3.1)
10.26.3.2 Company Sublease Agreement, dated as of August 1,
1990, between the Company, as Sublessor, and
NYCIDA A (10.31.3.2)
10.26.3.3 Indenture of Trust, dated as of August 1, 1990,
between NYCIDA and US Trust, as Trustee A (10.31.3.3)
10.26.3.4 Guaranty Agreement, dated as of August 1, 1990,
from the Company to US Trust, as Trustee A (10.31.3.4)
10.26.3.5 Tax Regulatory Agreement, dated August 1, 1990,
from the Company and NYC.IDA to US Trust, as
Trustee A(10.31.3.5)
10.26.3.6 Agency Security Agreement, dated as of August 1,
1990, from the Company, as Debtor, and the NYCIDA
to US Trust, as Trustee A(10.31.3.6)
10.26.3.7 Letter of Representation and Indemnity Agreement,
dated as of August 14, 1990, from the Company to
NYCIDA, New York Mutual Fund, Inc., as the
Purchaser and Chase Securities, Inc., as Placement
Agent Company to NYCIDA A(10.31.3.7)
10.27 Lease Agreement between 180 Varick Street
Corporation and the Company, dated October 8,
1985, and Additional Space and Modification
Agreement between 180 Varick Street Corporation
and the Company, dated June 13, 1989 A(10.32)
10.28 License Agreement between The Board of Trustees of
the Leland Stanford Junior University and the
Company effective May 1, 1991 A(10.33)
10.29 License Agreement between Genentech, Inc. and the
Company dated December 28, 1989 A(10.34)
10.30 License Agreement between David Segev and the
Company dated December 28, 1989 B(10.35)
10.31 Letter of Intent between the Company and Dr. David
Segev dated November 18, 1991 C(10.40)
10.32 Agreement between the Company and Celltech Limited
dated March 11, 1992 C(10.42)
10.33 Agreement of Sale dated June 19, 1992 between the
Company and Korsch Tableting Inc. D(10.45)
10.34 Research and License Agreement, having an
effective date of December 15, 1992, between the
Company and Abbott Laboratories E(10.46)
10.35 Research and License Agreement between the Company
and Chugai Pharmaceutical Co., Ltd. dated January
25, 1993 E(10.47)
22
10.36 License Agreement between the Company and the
Regents of the University of California dated
April 9, 1993 G (10.48)
10.37 Contract between the Company and John Brown, a
division of Trafalgar House, dated January 19,
1993 H (10.49)
10.38 Collaboration and License Agreement between the
Company and the Cancer Research Campaign
Technology, Ltd., signed April 4, 1994, with an
effective date of April 1, 1994. G (10.50)
10.39 Termination Agreement between the Company and
Erbamont Inc. dated July 21, 1993 H (10.51)
10.40 Research and License Agreement between the Company
and Cyanamid dated September 15, 1993 G (10.52)
10.41 Clinical Trials Agreement between the Company and
the National Cancer Institute dated November 23,
1993 H (10.53)
10.42 License Agreement between the Company and UNC
dated December 1, 1993 G (10.54)
10.43 Notice of Termination for the research
collaboration between the Company and Chugai
Pharmaceutical Co., Ltd. dated December 17, 1993 H (10.55)
10.44 License Agreement between the Company and
Rhone-Poulenc Rorer dated June 13, 1994 I (10.56)
10.45 Offshore Securities Subscription Agreement between
ImClone Systems Incorporated and GFL Ultra Fund
Limited dated August 12, 1994 I (10.57)
10.46 Offshore Securities Subscription Agreement between
ImClone Systems Incorporated and GFL Ultra Fund
Limited dated November 4, 1994 I (10.58)
10.47 Offshore Securities Subscription Agreement between
ImClone Systems Incorporated and Anker Bank
Zuerich dated November 10, 1994 I (10.59)
10.48 Option Agreement, dated as of April 27, 1995,
between ImClone Systems Incorporated and High
River Limited Partnership relating to capital
stock of Cadus Pharmaceutical Corporation J (10.60)
10.49 Option Agreement, dated as of April 27, 1995,
between ImClone Systems Incorporated and High
River Limited Partnership relating to 300,000
shares of Common Stock of ImClone Systems
Incorporated J (10.61)
10.50 Option Agreement, dated as of April 27, 1995,
between ImClone Systems Incorporated and High
River Limited Partnership relating to 150,000
shares Common Stock of ImClone Systems
Incorporated J (10.62)
10.51 Stock Purchase Agreement, dated as of August 10,
1995, by and between ImClone Systems Incorporated
and the members of the Oracle Group J (10.63)
10.52 Form of Warrant issued to the members of the
Oracle Group J (10.64)
10.53 Loan Agreement, dated as of August 10, 1995, by
and between ImClone Systems Incorporated and the
members of the Oracle Group J (10.65)
10.54 Security Agreement, dated as of August 10, 1995,
by and between ImClone Systems Incorporated and
the members of the Oracle Group J (10.66)
10.55 Mortgage, dated August 10, 1995, made by ImClone
Systems Incorporated for the benefit of Oracle
Partners, L.P., as Agent J (10.67)
10.56 Financial Advisory Agreement entered into between
the Company and Genesis Merchant Group Securities
dated November 2, 1995 K (10.68)
10.57 Repayment Agreement (with Confession of Judgment,
and Security Agreement) entered into between the
Company and Pharmacia, Inc. on March 6, 1996 K (10.69)
10.58 License Amendment entered into between the Company
and Abbott Laboratories on August 28,
1995,amending the Research and License Agreement
between the parties dated December 15, 1992 K (10.70
10.59 Amendment of September 1993 to the Research and
License Agreement between the Company and Merck of
April 1, 1990 K (10.71)
10.60 Amendment of October 1993 to the Research and
License Agreement between the Company and Merck of
April 1, 1990 K (10.72)
10.61 Employment agreement dated May 17, 1996 between
the Company and Carl S. Goldfischer L (10.73)
10.62 Financial Advisory Agreement dated February 26,
1997 between the Company and Hambrecht & Quist LLC L (10.74)
10.63 Exchange Agreement exchanging debt for Common
Stock dated as of April 15, 1996 among the Company
and members of The Oracle Group. L (10.75)
10.64 Collaborative Research and License Agreement
between the Company and CombiChem, Inc. dated
October 10, 1997 L (10.76)
23
10.65 Amendment of May 1996 to Research and License
Agreement between the Company and Merck of April
1, 1990 O
10.66 Amendment of December 1997 to Research and License
Agreement between the Company and Merck of April
1, 1990 O
21.1 Subsidiaries P
23.1 Consent of KPMG Peat Marwick LLP P
27.1 Financial Data Schedule P
99.1 1996 Incentive Stock Option Plan, as amended N (99.1)
99.2 1996 Non-Qualified Stock Option Plan, as amended N (99.2)
- ----------
A Previously filed with the Commission; incorporated by reference to
Registration Statement on Form S-1, File No. 33-43064.
B Previously filed with the Commission; incorporated by reference to
Registration Statement on Form S-1, File No. 33-43064. Confidential
treatment was granted for a portion of this exhibit.
C Previously filed with the Commission; incorporated by reference to
Registration Statement on Form S-1, File No. 33-48240. Confidential
treatment was granted for a portion of this exhibit.
D Previously filed with the Commission; incorporated by reference to the
Company's Annual Report on Form 10-K, filed June 26, 1992.
E Previously filed with the Commission; incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1992. Confidential treatment was granted for a portion of this
Exhibit.
F Previously filed with the Commission; incorporated by reference Amendment
No. 1 to Registration Statement on to Form S-1, File No. 33-61234.
G Previously filed with the Commission; incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1993. Confidential Treatment was granted for a portion of this
Exhibit.
H Previously filed with the Commission; incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1993.
I Previously filed with the Commission; incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1994.
J Previously filed with the Commission; incorporated by reference to
Registration Statement on Form S-2, File No. 33-98676.
K Previously filed with the Commission, incorporated by reference to the
Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1996.
L Previously filed with the Commission; incorporated by reference to the
Company's Quarterly Report on Form 10-Q for the quarter ended September
30, 1997, as amended. Confidential treatment was granted for a portion of
this Exhibit.
M Previously filed with the Commission; incorporated by reference to the
Company's Current Report on Form 8-K dated January 21, 1998.
N Previously filed with the Commission; incorporated by reference to the
Company's Quarterly Report on Form 10-Q for the quarter ended June 30,
1997.
O Filed herewith. Confidential treatment has been requested with respect to
certain portions of this Exhibit.
P Filed herewith.
24
(b) Reports on Form 8-K
On December 9, 1997, the Company filed with the Securities and Exchange
Commission (the "Commission") a Current Report on Form 8-K dated December 4,
1997 relating to the Company's entering into an amendment with Merck to the
Company's Research and License Agreement with Merck and the purchase by Merck
from the Company of 400,000 shares of Series A Preferred Stock (Item 5).
On October 15, 1997, the Company filed with the Commission a Current
Report on Form 8-K dated October 10, 1997 relating to the Company's entering
into a Collaborative Research and License Agreement with CombiChem and the
purchase of shares of CombiChem Common Stock (Item 5).
25
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
IMCLONE SYSTEMS INCORPORATED
March 27, 1998 By /s/ Samuel D. Waksal
----------------------------------
Samuel D. Waksal
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
Report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the date indicated.
Signature Title Date
--------- ----- ----
/s/ Robert F. Goldhammer Chairman of the Board of Directors March 27, 1998
- --------------------------
(Robert F. Goldhammer)
/s/ Samuel D. Waksal President, Chief Executive Officer March 27, 1998
- -------------------------- and Director
(Samuel D. Waksal) (Principal Executive Officer)
/s/ Harlan W. Waksal Executive Vice President, March 27, 1998
- -------------------------- Chief Operating Officer and Director
(Harlan W. Waksal)
/s/ Carl S. Goldfischer Vice President, Financial and March 27, 1998
- -------------------------- Strategic Planning and Chief Financial
(Carl S. Goldfischer) Officer (Principal Financial Officer)
/s/ Richard Barth Director March 27, 1998
- --------------------------
(Richard Barth)
/s/ Jean Carvais Director March 27, 1998
- --------------------------
(Jean Carvais)
/s/ Vincent T. DeVita, Jr. Director March 27, 1998
- --------------------------
(Vincent T. DeVita, Jr.)
/s/ David M. Kies Director March 27, 1998
- --------------------------
(David M. Kies)
__________________________ Director March 27, 1998
(Paul B. Kopperl)
/s/ John Mendelsohn Director March 27, 1998
- --------------------------
(John Mendelsohn)
/s/ William R. Miller Director March 27, 1998
- --------------------------
(William R. Miller)
26
FINANCIAL STATEMENTS
Index to Financial Statements
Financial Statements
Independent Auditors' Report ............................................. F-2
Balance Sheets at December 31, 1997 and 1996 ............................. F-3
Statements of Operations for the Years Ended
December 31, 1997, 1996, and 1995 ....................................... F-4
Statements of Stockholders' Equity for the Years
Ended December 31, 1997, 1996, and 1995 ................................. F-5
Statements of Cash Flows for the Years Ended
December 31, 1997, 1996, and 1995 ....................................... F-6
Notes to Financial Statements ............................................ F-7
F-1
INDEPENDENT AUDITORS' REPORT
The Board of Directors of ImClone Systems Incorporated:
We have audited the financial statements of ImClone Systems Incorporated
as listed in the accompanying index. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of ImClone Systems Incorporated
as of December 31, 1997 and 1996, and the results of its operations and its cash
flows for each of the years in the three-year period ended December 31, 1997, in
conformity with generally accepted accounting principles.
/s/ KPMG Peat Marwick LLP
----------------------------
KPMG Peat Marwick LLP
New York, New York
February 20, 1998
F-2
IMCLONE SYSTEMS INCORPORATED
Balance Sheets
(in thousands, except share data)
December 31, December 31,
Assets 1997 1996
----------- ------------
Current assets:
Cash and cash equivalents ......................... $ 2,558 $ 2,734
Securities available for sale ..................... 57,052 10,780
Prepaid expenses .................................. 596 122
Amount due from officer and stockholder ........... -- 101
Other current assets .............................. 589 479
--------- ---------
Total current assets ............. 60,795 14,216
--------- ---------
Property and equipment:
Land .............................................. 340 340
Building and building improvements ................ 8,969 8,969
Leasehold improvements ............................ 4,832 4,832
Machinery and equipment ........................... 6,315 5,159
Furniture and fixtures ............................ 550 536
Construction in progress .......................... 2,159 320
--------- ---------
Total cost ....................... 23,165 20,156
Less accumulated depreciation
and amortization ........................... (11,294) (9,606)
--------- ---------
Property and equipment, net ...... 11,871 10,550
--------- ---------
Patent costs, net ...................................... 944 977
Deferred financing costs, net .......................... 55 65
Other assets ........................................... 2,115 77
--------- ---------
$ 75,780 $ 25,885
========= =========
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable .................................. $ 1,731 $ 1,059
Accrued expenses and other ........................ 1,440 1,366
Interest payable .................................. 68 238
Deferred revenue .................................. 208 --
Current portion of long-term liabilities .......... 677 3,858
--------- ---------
Total current liabilities ........ 4,124 6,521
--------- ---------
Long-term debt ......................................... 2,200 2,200
Other long-term liabilities, less current portion ...... 1,230 575
--------- ---------
Total liabilities ................ 7,554 9,296
--------- ---------
Commitments and contingencies
Stockholders' equity:
Preferred stock, $1.00 par value; authorized
4,000,000 shares; issued and outstanding
Series A Convertible: 400,000 and none
at December 31, 1997 and December 31, 1996,
respectively (preference in liquidation
$40,112 and none, respectively) ............. 400 --
Common stock, $.001 par value; authorized
45,000,000 shares; issued 24,265,072
and 20,248,122 at December 31, 1997 and
December 31, 1996, respectively;
outstanding 24,214,255 and
20,233,699 at December 31, 1997 and
December 31, 1996, respectively .............. 24 20
Additional paid-in capital ........................ 185,706 118,760
Accumulated deficit ............................... (117,464) (101,973)
Treasury stock, at cost; 50,817 and 14,423
shares at December 31, 1997
and December 31, 1996, respectively .......... (492) (169)
Unrealized gain (loss) on securities
available for sale ........................... 52 (49)
--------- ---------
Total stockholders' equity ....... 68,226 16,589
--------- ---------
$ 75,780 $ 25,885
========= =========
See accompanying notes to financial statements.
F-3
IMCLONE SYSTEMS INCORPORATED
Statements of Operations
(in thousands, except per share data)
Year Ended December 31,
-------------------------------
1997 1996 1995
------- -------- --------
Revenues:
License fees from third parties ...... $ 3,000 $ 75 $ --
Research and development funding
from third parties and other ........ 2,348 525 800
-------- -------- --------
Total revenues ..................... 5,348 600 800
-------- -------- --------
Operating expenses:
Research and development ............. 16,455 11,482 8,768
General and administrative ........... 5,356 3,961 3,739
-------- -------- --------
Total operating expenses ........... 21,811 15,443 12,507
-------- -------- --------
Operating loss ......................... (16,463) (14,843) (11,707)
-------- -------- --------
Other:
Interest and other income ............ (1,523) (918) (3,120)
Interest expense ..................... 551 823 1,054
-------- -------- --------
Net interest and other income ...... (972) (95) (2,066)
-------- -------- --------
Loss before extraordinary item ......... (15,491) (14,748) (9,641)
Extraordinary loss on
extinguishment of debt ................ -- 1,267 --
-------- -------- --------
Net loss ............................... (15,491) (16,015) (9,641)
Preferred dividends (including
incremental yield of $51) ............. 163 -- --
-------- -------- --------
Net loss to common stockholders ........ $(15,654) $(16,015) $ (9,641)
======== ======== ========
Net loss per common share:
Basic and diluted:
Loss before extraordinary item ..... $ (0.67) $ (0.76) $ (0.72)
Extraordinary loss on
extinguishment of debt ............ -- 0.07 --
-------- -------- --------
Net loss ............................. $ (0.67) $ (0.83) $ (0.72)
======== ======== ========
Weighted average shares outstanding .... 23,457 19,371 13,311
======== ======== ========
See accompanying notes to financial statements.
F-4
IMCLONE SYSTEMS INCORPORATED
Statements of Stockholders' Equity
Years Ended December 31, 1995, 1996, and 1997
(in thousands, except share data)
Preferred Stock Common Stock Additional
------------------------- -------------------------- Paid-in Accumulated
Shares Amount Shares Amount Capital Deficit
---------- ----------- ----------- ----------- ----------- -----------
Balance at December 31, 1994 ....... -- $ -- 12,577,685 $ 13 $ 84,630 $ (76,317)
----------- ----------- ----------- ----------- ----------- -----------
Issuance of common stock ............ 4,000,000 4 11,998
Options exercised ................... 156,750 162
Warrants exercised .................. 15,300 23
Payment of promissory notes ......... 57,184 36
Proceeds from promissory notes ...... 2
Debt discount ....................... 1,063
Net loss ............................ (9,641)
----------- ----------- ----------- ----------- ----------- -----------
Balance at December 31, 1995 ....... -- $ -- 16,806,919 $ 17 $ 97,914 $ (85,958)
----------- ----------- ----------- ----------- ----------- -----------
Issuance of common stock ............ 2,200,000 2 13,560
Options exercised ................... 266,275 846
Warrants exercised .................. 604,892 1 2,960
Options granted to non-employees .... 95
Extinguishment of debt .............. 357,333 3,260
Debt discount ....................... 125
Treasury shares ..................... (1,720)
Changes in unrealized loss on
securities available for sale ...
Net loss ............................ (16,015)
----------- ----------- ----------- ----------- ----------- -----------
Balance at December 31, 1996 ....... -- $ -- 20,233,699 $ 20 $ 118,760 $ (101,973)
----------- ----------- ----------- ----------- ----------- -----------
Issuance of preferred stock ......... 400,000 400 39,597
Issuance of common stock ............ 3,000,000 3 23,152
Options exercised ................... 147,450 223
Warrants exercised .................. 869,500 1 1,385
Options granted to non-employees .... 189
Options/warrants granted to
employees .......................... 2,512
Treasury shares ..................... (36,394)
Changes in unrealized gain on
securities available for sale ...
Preferred stock dividends ........... (112)
Net loss ............................ (15,491)
----------- ----------- ----------- ----------- ----------- -----------
Balance at December 31, 1997 ....... 400,000 $ 400 24,214,255 $ 24 $ 185,706 $ (117,464)
=========== =========== =========== =========== =========== ===========
Unrealized
(Loss) on
Securities
Treasury Available
Stock for Sale Total
---------- ----------- -----------
Balance at December 31, 1994 ....... $ (150) $ -- $ 8,176
---------- ----------- -----------
Issuance of common stock ............ 12,002
Options exercised ................... 162
Warrants exercised .................. 23
Payment of promissory notes ......... 36
Proceeds from promissory notes ...... 2
Debt discount ....................... 1,063
Net loss ............................ (9,641)
---------- ----------- -----------
Balance at December 31, 1995 ....... $ (150) $ -- $ 11,823
---------- ----------- -----------
Issuance of common stock ............ 13,562
Options exercised ................... 846
Warrants exercised .................. 2,961
Options granted to non-employees .... 95
Extinguishment of debt .............. 3,260
Debt discount ....................... 125
Treasury shares ..................... (19) (19)
Changes in unrealized loss on
securities available for sale ... (49) (49)
Net loss ............................ (16,015)
---------- ----------- -----------
Balance at December 31, 1996 ....... $ (169) $ (49) $ 16,589
---------- ----------- -----------
Issuance of preferred stock ......... 39,997
Issuance of common stock ............ 23,155
Options exercised ................... 223
Warrants exercised .................. 1,386
Options granted to non-employees .... 189
Options/warrants granted to
employees .......................... 2,512
Treasury shares ..................... (323) (323)
Changes in unrealized gain on
securities available for sale ... 101 101
Preferred stock dividends ........... (112)
Net loss ............................ (15,491)
---------- ----------- -----------
Balance at December 31, 1997 ....... $ (492) $ 52 $ 68,226
========== =========== ===========
See accompanying notes to financial statements.
F-5
IMCLONE SYSTEMS INCORPORATED
Statements of Cash Flows
(in thousands)
Year Ended December 31,
------------------------------------
1997 1996 1995
---------- ---------- ----------
Cash flows from operating activities:
Net loss .............................................. $ (15,491) $ (16,015) $ (9,641)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization ....................... 1,797 1,704 1,789
Expense associated with issuance
of options and warrants ......................... 2,729 95 --
Extraordinary loss on extinguishment of debt ........ -- 1,267 --
Discounted interest amortization .................... -- 156 222
Write-off of fixed assets ........................... -- -- 2
Write-off of patent costs ........................... 146 -- 126
Loss on sale of investments ......................... 2 -- --
Changes in:
Prepaid expenses .................................. (474) (7) (37)
Other current assets .............................. (110) (453) 42
Due from officer .................................. 101 31 24
Other assets ...................................... (37) (14) 115
Interest payable .................................. (170) (105) 328
Accounts payable .................................. 672 67 (624)
Accrued expenses and other ........................ 75 540 421
Deferred revenue .................................. 208 -- --
--------- --------- ---------
Net cash used in operating activities .......... (10,552) (12,734) (7,233)
--------- --------- ---------
Cash flows from investing activities:
Acquisitions of property and equipment ................ (1,657) (272) (36)
Purchases of securities available for sale ............ (241,623) (32,665) --
Sales of securities available for sale ................ 195,450 21,836 --
Investment in CombiChem, Inc .......................... (2,000) -- --
Additions to patents .................................. (212) (343) (186)
--------- --------- ---------
Net cash used in investing activities .......... (50,042) (11,444) (222)
--------- --------- ---------
Cash flows from financing activities:
Net proceeds from issuance of preferred stock ......... 39,997 -- --
Net proceeds from issuance of common stock ............ 23,154 13,562 12,002
Proceeds from exercise of stock options and
warrants............................................ 1,581 3,807 185
Purchase of treasury stock ............................ (323) (19) --
Proceeds from long-term notes payable ................. -- -- 2,680
Proceeds from short-term notes payable ................ -- -- 100
Repayment of long-term debt ........................... (2,113) -- --
Repayment of short-term notes payable ................. -- -- (284)
Payments of other liabilities ......................... (1,878) (645) (53)
--------- --------- ---------
Net cash provided by financing activities ..... 60,418 16,705 14,630
--------- --------- ---------
Net (decrease) increase in cash and cash equivalents .... (176) (7,473) 7,175
Cash and cash equivalents at beginning of period ........ 2,734 10,207 3,032
--------- --------- ---------
Cash and cash equivalents at end of period .............. $ 2,558 $ 2,734 $ 10,207
========= ========= =========
See accompanying notes to financial statements.
F-6
IMCLONE SYSTEMS INCORPORATED
Notes To Financial Statements
(1) Organization and Basis of Preparation
ImClone Systems Incorporated (the "Company") is a biopharmaceutical
company engaged primarily in the research and development of therapeutic
products for the treatment of cancer and cancer related disorders. The Company
employs accounting policies that are in accordance with generally accepted
accounting principles in the United States.
The biopharmaceutical industry is subject to rapid and significant
technological change. The Company has numerous competitors, including major
pharmaceutical and chemical companies, specialized biotechnology firms,
universities and other research institutions. These competitors may succeed in
developing technologies and products that are more effective than any that are
being developed by the Company or that would render the Company's technology and
products obsolete and non-competitive. Many of these competitors have
substantially greater financial and technical resources and production and
marketing capabilities than the Company. In addition, many of the Company's
competitors have significantly greater experience than the Company in
pre-clinical testing and human clinical trials of new or improved pharmaceutical
products and in obtaining Food and Drug Administration ("FDA") and other
regulatory approvals on products for use in health care. The Company is aware of
various products under development or manufactured by competitors that are used
for the prevention, diagnosis or treatment of certain diseases the Company has
targeted for product development, some of which use therapeutic approaches that
compete directly with certain of the Company's product candidates. The Company
has limited experience in conducting and managing pre-clinical testing necessary
to enter clinical trials required to obtain government approvals and has limited
experience in conducting clinical trials. Accordingly, the Company's competitors
may succeed in obtaining FDA approval for products more rapidly than the
Company, which could adversely affect the Company's ability to further develop
and market its products. If the Company commences significant commercial sales
of its products, it will also be competing with respect to manufacturing
efficiency and marketing capabilities, areas in which the Company has limited or
no experience.
(2) Summary of Significant Accounting Policies
(a)Cash Equivalents
Cash equivalents consist primarily of U.S. Government instruments,
commercial paper, master notes and other readily marketable debt instruments.
The Company considers all highly liquid debt instruments with original
maturities not exceeding three months to be cash equivalents.
(b) Investments in Securities
The Company classifies its investment in debt and equity securities in one
of three categories: trading, available-for-sale, or held-to-maturity. Trading
securities are bought and held principally for the purpose of selling them in
the near term. Held-to-maturity securities are those securities in which the
Company has the ability and intent to hold the security until maturity. All
other securities not included in trading or held-to-maturity are classified as
available-for-sale.
Trading and available-for-sale securities are recorded at fair value.
Held-to-maturity securities are recorded at amortized cost, adjusted for the
amortization or accretion of premiums or discounts. Unrealized holding gains and
losses on trading securities are included in earnings. Unrealized holding gains
and losses, net of related tax effect, on available-for-sale securities are
excluded from earnings and are reported as a separate component of stockholders'
equity until realized. Realized gains and losses from the sale of
available-for-sale securities are determined on a specific identification basis.
A decline in the market value of any available-for-sale or
held-to-maturity security below cost that is deemed to be other than temporary
results in a reduction in carrying amount to fair value. The impairment is
charged to earnings and a new cost basis for the security is established.
Premiums and discounts are amortized or accreted over the life of the related
held-to-maturity security as an adjustment to yield using the effective interest
method. Dividend and interest income are recognized when earned.
At December 31, 1997, all investments in securities were classified as
available-for-sale.
F-7
(c) Long-Lived Assets
Long-lived assets include:
o Fixed assets are stated at cost. Depreciation of fixed assets is
provided by straight-line methods over estimated useful lives of three
to twelve years, and leasehold improvements are being amortized over
the related lease term (including optional renewal periods (Note 12))
or the service lives of the improvements, whichever is shorter.
o Patent and patent application costs are amortized on a straight-line
basis over their respective expected useful lives, up to a 15-year
period. Capitalized patent costs are reviewed for impairment whenever
events or circumstances provide evidence that suggests that the
carrying amount may not be recoverable. The Company assesses the
recoverability of net capitalized patent costs by determining if the
unamortized balance can be recovered through future cash flows.
The Company reviews long-lived assets for impairment when events or
changes in business conditions indicate that their full carrying value may not
be recovered. Assets are considered to be impaired and written down to fair
value if expected associated cash flows are less than the carrying amounts. Fair
value is generally the present value of the expected associated cash flows.
(d) Deferred Financing Costs
Costs incurred in obtaining the Industrial Development Revenue Bonds (Note
6) are amortized using the straight-line method over the terms of the related
bonds.
(e) Gain on Sale of Investment in Affiliate
Cadus Pharmaceutical Corporation ("Cadus") was incorporated in January
1992 to develop novel classes of therapeutics that target signal transduction
pathways. The Company held a 50% investment in the capital stock of Cadus
through November 1994. During 1994 and 1995, the Company sold its capital stock
holding in Cadus to High River Limited Partnership ("High River"). The Statement
of Operations for the year ended December 31, 1995 includes in interest and
other income the gain on the sale of the Cadus stock sold during that period. In
exchange for receiving a now-expired right to repurchase all the outstanding
shares of capital stock of Cadus held by High River, the Company granted to High
River two options to purchase shares of the Company's common stock (the "Common
Stock"). One option is for 150,000 shares at an exercise price per share equal
to $2.00, subject to adjustment under certain circumstances, and the other
option is for 300,000 shares at an exercise price per share equal to $0.69,
subject to adjustment under certain circumstances. Both options will expire on
April 26, 2000.
(f) Revenue Recognition
License fees are recognized if the Company enters into license agreements
with third parties that provide for the payment of non-refundable fees when the
agreement is signed or when all parties concur that specified goals are
achieved. These fees are recognized as license fee revenues in accordance with
the terms of the particular agreement.
Research and development funding revenue is derived from collaborative
agreements with third parties and is recognized in accordance with the terms of
the respective contracts. Revenue from certain agreements is recognized using
the percentage of completion method based on contract costs incurred to date
compared with total estimated contract costs.
Royalty revenue is recognized upon receipt by the Company and is derived
from sales of products by corporate partners using licensed Company technology.
Revenue recognized in the accompanying statements of operations is not
subject to repayment. Revenue received that is related to future performance
under such contracts is deferred and recognized as revenue when earned.
(g) Stock Option Plans
Prior to January 1, 1996, the Company accounted for its stock option plans
in accordance with the provisions of Accounting Principles Board ("APB") Opinion
No. 25, Accounting for Stock Issued to Employees, and related interpretations.
As such, compensation expense would be recorded on the date of grant only if the
market price on the date of grant of the underlying stock exceeded the exercise
price. On January 1, 1996, the Company adopted Statement of Financial Accounting
Standards No. ("SFAS") 123, "Accounting for Stock-Based Compensation,"
F-8
which permits entities to recognize as expense over the vesting period the fair
value of all stock based awards on the date of grant. Alternatively, SFAS No.
123 also allows entities to continue to apply the provisions of APB Opinion No.
25 and provide pro forma net income and pro forma earnings per share disclosures
for employee stock option grants made in 1995 and future years as if the
fair-value-based method defined in SFAS No. 123 had been applied. The Company
has elected to continue to apply the provisions of APB Opinion No. 25 and
provide the pro forma disclosure provisions of SFAS No. 123.
(h) Research and Development
Research and development expenditures made pursuant to certain research
and development contracts with academic institutions, and other research and
development costs, are expensed as incurred.
(i) Income Taxes
Income taxes are accounted for under the asset and liability method.
Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date.
(j) Use of Estimates
Management of the Company has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the disclosure of
contingent assets and liabilities to prepare these financial statements in
conformity with generally accepted accounting principles. Actual results could
differ from those estimates.
(k) Net Loss Per Share
The Company adopted the provisions of SFAS No. 128, "Earnings Per Share"
("EPS") for the year ended December 31, 1997. This statement simplifies the
standards for computing EPS and makes them more comparable to international EPS
standards. It replaces the presentation of primary EPS with a presentation of
basic EPS and requires dual presentation of basic and diluted EPS on the face of
the statement of operations of all entities with complex capital structures.
SFAS 128 also requires a reconciliation of the numerator and denominator of the
diluted EPS calculation. Potentially dilutive securities, including convertible
preferred stock, options and warrants, have not been included in the diluted EPS
computation because they are anti-dilutive.
(l) Reclassification
Certain amounts previously reported have been reclassified to conform to
current year's presentation.
F-9
(3) Securities Available-For-Sale
The amortized cost, gross unrealized holding gains, gross unrealized
holding losses and fair value for available-for-sale securities by major
security type at December 31, 1997 and 1996, were as follows:
At December 31, 1997:
Gross
Unrealized Gross
Amortized Holding Unrealized
Cost Gains Holding Losses Fair Value
---- ----- -------------- ----------
Commercial paper ........................ $ 12,104,000 $ 4,000 $ -- $ 12,108,000
U.S. Government debt .................... 23,568,000 24,000 (5,000) 23,587,000
U.S. corporate debt ..................... 3,992,000 4,000 -- 3,996,000
Foreign corporate debt .................. 4,719,000 7,000 -- 4,726,000
Foreign Government/Agency
guaranteed debt......................... 12,617,000 18,000 -- 12,635,000
------------ ------------ ------------ ------------
$ 57,000,000 $ 57,000 $ (5,000) $ 57,052,000
============ ============ ============ ============
At December 31, 1996:
U.S. Government debt .................... $ 10,829,000 $ -- $ (49,000) $ 10,780,000
============ ============ ============ ============
Maturities of debt securities classified as available-for-sale were as
follows at December 31, 1997:
Years Ended December 31,
Amortized Cost Fair Value
-------------- ----------
1998 ...................... $25,849,000 $25,859,000
1999 ...................... 6,984,000 6,983,000
2000 ...................... 24,167,000 24,210,000
----------- -----------
$57,000,000 $57,052,000
=========== ===========
Proceeds from the sale of investment securities available-for-sale were
$195,450,000 and $21,836,000 in 1997 and 1996, respectively. Gross realized
gains included in income in 1997 were $1,000 and gross realized losses included
in income 1997 were $3,000. There were no realized gains or losses in 1996.
F-10
(4) Other Assets
The following items are included in other assets:
December 31, December 31,
1997 1996
---------- ----------
Deposits ....................................... $ 115,000 $ 77,000
Investment in CombiChem, Inc. .................. 2,000,000 --
---------- ----------
$2,115,000 $ 77,000
========== ==========
In October 1997, the Company entered into a Collaborative Research and
License Agreement with CombiChem, Inc. ("CombiChem"), a private company, to
discover and develop novel small molecules for use against selected targets for
the treatment of cancer. The companies are utilizing CombiChem's Discovery
EngineTM and Universal Informer LibraryTM to generate small-molecules for
screening in the Company's assays for identification of lead candidates. The
Company is providing CombiChem with research funding through October 1999 in the
amount of $500,000 annually (of which the first $500,000 was paid in October
1997), milestone payments and royalties on marketed products resulting from the
collaboration, if any. Concurrent with the execution of the Collaborative
Research and License Agreement, the Company entered into a Stock Purchase
Agreement pursuant to which the Company purchased 250,000 shares of common stock
of CombiChem, as adjusted, for aggregate consideration of $2,000,000. The
Company has recorded its investment in CombiChem using the cost method of
accounting which approximates market value.
(5) Accrued Expenses and Other
The following items are included in accrued expenses and other:
December 31, December 31,
1997 1996
----------- -----------
Salaries and other payroll
related expenses ............................. $ 773,000 $ 782,000
Legal and accounting fees ...................... 169,000 217,000
Other .......................................... 498,000 367,000
========== ==========
$1,440,000 $1,366,000
========== ==========
(6) Long-term Debt
Long-term debt consists of the following:
December 31, December 31,
1997 1996
----------- -----------
10.75% Bond due 1997 .......................... $ -- $ 2,113,000
11.25% Bond due 2004 ........................... 2,200,000 2,200,000
----------- -----------
2,200,000 4,313,000
Less current portion ........................... -- (2,113,000)
=========== ===========
$ 2,200,000 $ 2,200,000
=========== ===========
On December 31, 1986, the New York City Industrial Development Agency (the
"NYIDA") issued on behalf of the Company an Industrial Development Revenue Bond
(the "1986 Bond") in the amount of $2,113,000 with a
F-11
maturity date of December 15, 1994. The proceeds from the sale of the 1986 Bond
were used by the Company for the acquisition, construction and installation of
the Company's research and development facility in New York City. During
December 1994, the 1986 Bond's original maturity date of December 15, 1994 was
extended to June 15, 1996. During June 1996, the Company and the NYIDA extended
the maturity date an additional eighteen months to December 15, 1997. The
Company repaid the obligation on December 15, 1997.
In August 1990, the NYIDA issued another Industrial Development Revenue
Bond (the "1990 Bond") in the amount of $2,200,000. The 1990 Bond is due May 1,
2004. If the Company terminates its lease on its New York City facility (the
"Lease") the 1990 Bond will become due 60 days prior to such date. The Lease is
scheduled to expire in March 1999 and the Company is currently in discussions
regarding its extension and considering other alternatives. The proceeds from
the sale of the 1990 Bond were used by the Company for the acquisition,
construction and installation of the Company's research and development facility
in New York City.
The Company has granted a security interest in substantially all equipment
located in its New York City facility to secure the obligations of the Company
to the NYIDA relating to the 1990 Bond. Interest expense on the 1986 and 1990
Bonds for the years ended December 31, 1997 and 1996 was $465,000 and $475,000
respectively.
(7) Other Long-term Liabilities
Other long-term liabilities are comprised of the following:
December 31, December 31,
1997 1996
----------- -----------
Liability to reacquire IL-6m rights .......... $ 283,000 $ 1,917,000
Liability under capital lease obligations .... 1,469,000 354,000
Liability under license agreement ............ 43,000 49,000
Preferred stock dividends payable ............ 112,000 --
----------- -----------
1,907,000 2,320,000
Less current portion ......................... (677,000) (1,745,000)
----------- -----------
$ 1,230,000 $ 575,000
=========== ===========
In July 1993, the Company entered into an agreement with Erbamont, Inc.,
now a subsidiary of Pharmacia and Upjohn, Inc. ("Pharmacia"), to acquire the
worldwide rights to IL-6m, a blood cell growth factor, which had been licensed
to Pharmacia pursuant to a development and licensing agreement. In consideration
of the return of rights and the transfer of certain material and information,
the Company had paid $1.4 million and had further obligations to Pharmacia
totaling $283,000 at December 31, 1997. In February 1998, such amount was paid
off in its entirety. In addition, the Company is required to pay Pharmacia up to
$2.7 million in royalties on eventual sales of IL-6m, if any.
The Company is obligated under various capital leases for certain
laboratory, office and computer equipment and also certain building improvements
primarily under a December 1996 financing agreement with Finova Technology
Finance, Inc. ("Finova"). The agreement allows the Company to finance the lease
of equipment and make certain building and leasehold improvements to existing
facilities involving amounts aggregating approximately $2,500,000. As of
December 31, 1997, the Company had entered into six individual leases
aggregating a total cost of $1,745,000. Each lease has a fair market value
purchase option at the expiration of a 42-month term. Pursuant to the agreement,
the Company issued to Finova a warrant expiring December 31, 1999 to purchase
23,220 shares of Common Stock at an exercise price of $9.69 per share. The
Company recorded a non-cash debt discount of approximately $125,000 in
connection with this financing, which discount is being amortized over the
42-month term of the first lease. The financing agreement with Finova expired in
December 1997 and the Company did not utilize the full $2,500,000 under the
agreement. The Company anticipates that it will enter into a new financing
agreement with Finova during the second quarter of 1998 aggregating
approximately $2,000,000; however, no assurance can be given that such agreement
will be consummated. See Notes 12 and 14.
F-12
At December 31, 1997 and 1996, the gross amount of laboratory and office
equipment and building improvements and the related accumulated depreciation and
amortization recorded under all capital leases were as follows:
December 31, December 31,
1997 1996
----------- -----------
Laboratory, office and computer equipment ........ $ 1,204,000 $ 406,000
Building improvements ............................ 831,000 297,000
----------- -----------
2,035,000 703,000
Less accumulated depreciation and amortization ... (291,000) (190,000)
----------- -----------
$ 1,744,000 $ 513,000
=========== ===========
In connection with the Company's production and eventual marketing of
certain products, the Company entered into a license agreement that requires
minimum annual royalty payments throughout the term of the agreement. The
agreement expires in 2004 and calls for minimum annual payments of $10,000,
which are creditable against royalties that may be due from sales. To the extent
the minimum annual royalties are not expected to be offset by sales, the Company
has charged the net present value of these payments to operations. An interest
rate of 10% was used to discount the cash flows.
In July 1995, a director loaned the Company $180,000 in exchange for a
long-term note due two years from issuance at an annual interest rate of 8%. As
part of the transaction, the director was granted 36,000 warrants to purchase
Company Common Stock at $1.50 per share and an additional 36,000 warrants to
purchase Common Stock at $3.00 per share. In May 1996, the Company and the
director exchanged the note for 24,000 shares of Common Stock and the Company
paid the accrued and unpaid interest on the note in the amount of $10,000 in
cash. The Company recorded an extraordinary loss of $39,000 on the
extinguishment of the debt. The Company has registered such shares of Common
Stock with the Securities and Exchange Commission (the "Commission") under a
registration statement in accordance with the provisions of the Securities Act
of 1933 (the "1933 Act").
On August 11, 1995, the Oracle Group purchased 1,000,000 shares of Common
Stock for a purchase price of $1.5 million and made a loan to the Company in the
aggregate amount of $2.5 million with a two-year maturity, but subject to
mandatory prepayment, in whole or in part, upon the occurrence of certain
events, including the raising of certain additional funds. The loan carried an
annual interest rate of 8%. The Oracle Group includes Oracle Partners, LP,
Quasar International Partners C.V., Oracle Institutional Partners LP, Sam Oracle
Fund, Inc. and Warren B. Kanders. The Oracle Group also received warrants
exercisable at any time until August 10, 2000 entitling the holders thereof to
purchase 500,000 shares of Common Stock at a price of $1.50 per share and
500,000 shares of Common Stock at a price of $3.00 per share. As a result of the
Company's offerings of shares of its Common Stock in November 1995 and February
1996, the Oracle Group was entitled to require the Company to apply 20 percent
of the gross proceeds of the sale of the shares of Common Stock from the
offerings to repay the loan.
In May 1996, the Company and the Oracle Group exchanged the notes in the
aggregate outstanding principal amount of $2.5 million for 333,333 shares of
Common Stock and the Company paid the accrued and unpaid interest on the notes
in the amount of $143,000 in cash. The Company recorded an extraordinary loss of
$1,228,000 on the extinguishment of the debt. The Company has registered such
shares of Common Stock with the Commission under a registration statement in
accordance with the provisions of the 1933 Act.
(8) Research Agreements
The Company has entered into several research and development agreements
with third parties. Generally, the agreements provide for the Company to receive
research and development funding, milestone payments, royalties, or license fees
or a combination thereof. In return, the Company has granted licenses to these
third parties to market or manufacture and market certain of its products in
specified fields of use and in specified geographic areas. Pursuant to the
Company's research and license agreement with Merck KGaA ("Merck"), the Company
has the right to co-promote its BEC2 product in North America.
F-13
Revenues for the years ended December 31, 1997, 1996, and 1995 were
$5,348,000, $600,000, and $800,000 respectively. Revenues for each year
consisted of $300,000 in research support from the Company's corporate
partnership with the Wyeth-Lederle vaccine and pediatrics division of American
Home Products Corporation ("American Home") in infectious disease vaccines. The
year ended December 31, 1997 included $2,000,000 in milestone payments and
$1,667,000 in research and support payments from the Company's research and
license agreement with Merck. In addition, revenues for the years ended December
31, 1997 and 1995 included milestone payments of $1,000,000 and $500,000,
respectively, from the Company's strategic alliance with Abbott Laboratories
("Abbott") in diagnostics. The years ended December 31, 1997 and 1996 also
included royalty revenue of $381,000 and $225,000, respectively, from the Abbott
alliance. Finally, the year ended December 31, 1996 included $75,000 in license
fees from the Company's cross-licensing agreement with Immunex Corporation
("Immunex") for novel hematopoietic growth factors.
Revenues were derived from the following geographic areas:
Year Ended December 31,
---------------------------------------------
1997 1996 1995
---------- ---------- ----------
United States ............ $1,681,000 $ 600,000 $ 800,000
Europe ................... 3,667,000 -- --
---------- ---------- ----------
$5,348,000 $ 600,000 $ 800,000
========== ========== ==========
(9) Preferred Stock
In connection with the December 1997 amendment to the Company's research
and license agreement with Merck, Merck purchased from the Company in December
1997 400,000 shares of the Company's Series A Convertible Preferred Stock (the
"Series A Preferred Shares" or "Series A Preferred Stock") for total
consideration of $40,000,000, before issuance costs of $3,000. The holders of
the Series A Preferred Shares are entitled to receive annual cumulative
dividends of $6.00 per share. Dividends accrue as of the issuance date of the
Series A Preferred Shares and are payable on the outstanding Series A Preferred
Shares in cash annually on December 31 of each year beginning December 31, 1999
or at the time of conversion or redemption of the Series A Preferred Shares on
which the dividend is to be paid, whichever is sooner. Up to 100,000 Series A
Preferred Shares are currently convertible and an additional 100,000 Series A
Preferred Shares will become convertible on each of January 1, 2000, January 1,
2001 and January 1, 2002. During the period from issuance through December 31,
1999, the Series A Preferred Shares are convertible at a price equal to $12.50
per share; during the period from January 1, 2000 through December 31, 2000 the
Series A Preferred Shares are convertible at a price equal to the average of the
closing prices for the Common Stock for the five trading days ending on December
31, 1999; during the period from January 1, 2001 through December 31, 2001 the
Series A Preferred Shares are convertible at a price equal to the average of the
closing prices for the Common Stock for the five trading days ending on December
31, 2000; during the period from January 1, 2002 through December 31, 2002 the
Series A Preferred Shares are convertible at a price equal to 88% of the average
of the closing prices for the Common Stock for the five trading days ending on
December 31, 2001; and anytime after January 1, 2003 the Series A Preferred
Shares are convertible at a price equal to the average of the closing prices for
the Common Stock for the five trading days ending on December 31, 2002. The
conversion price is subject to adjustment in the case of certain dilutive
events. Further, in the event the average market price of the Common Stock for
the five consecutive trading days ending one trading day prior to any trading
day during which any Series A Preferred Shares are outstanding exceeds 150% of
the conversion price then in effect, the Company has the right to require the
holder of the Series A Preferred Shares to convert all such shares that may be
convertible. The Company may also redeem in whole or any part of the Series A
Preferred Shares then outstanding at a redemption price of $120 per Preferred
Share, plus accrued and unpaid dividends thereon. In the event of any voluntary
or involuntary liquidation, dissolution or winding up of the Company, the
holders of the Series A Preferred Shares shall be entitled to receive in cash
out of the assets of the Company, whether from capital or from earnings,
available for distribution to its stockholders, before any amount shall be paid
the holders of the Common Stock or holders of shares of other classes or series
of capital stock of the Company, an amount equal to the preference in
liquidation; provided that, if the assets are insufficient to pay the full
amount due to the holders of Series A Preferred Shares, such holders will
receive a pro rata portion thereof. In accordance with the terms of the Series A
Preferred Stock, the holder is able to realize an assured incremental yield of
$5,455,000 on the conversion of the Series A Preferred Stock if converted from
January 1, 2002 through December 31, 2002. Such amount is being amortized as a
preferred stock dividend over a five-year period beginning with the day of
issuance. Accrued dividends were $112,000 plus the incremental yield on the
conversion discount of $51,000 at December 31, 1997.
F-14
(10) Stock Options and Warrants
(a) Stock Option Plans:
In February 1986, the Company adopted and the shareholders thereafter
approved an Incentive Stock Option Plan and a Non-Qualified Stock Option Plan
(the "86 Plans"). In February 1996, the Company's Board of Directors adopted and
the shareholders thereafter approved an additional Incentive Stock Option Plan
and Non-Qualified Stock Option Plan (the "96 Plans"). Combined, the 86 Plans and
96 Plans, as amended, provide for the granting of options to purchase up to
4,500,000 shares of Common Stock to key employees, directors, consultants and
advisors of the Company. Incentive stock options may not be granted at a price
less than the fair market value of the stock at the date of grant and may not be
granted to non-employees. Options under both the 86 Plans and 96 Plans, unless
earlier terminated, expire ten years from the date of grant. Certain options
granted under these plans vest over one-to-five-year periods. At December 31,
1997, options to purchase 2,377,095 shares of Common Stock were outstanding and
1,592,156 shares were available for grant. Options may no longer be granted
under the 86 Plans pursuant to the terms of the Plans.
A summary of stock option activity follows:
Weighted
average
exercise
Number of price per
shares share
---------- ---------
Balance at December 31, 1994 ................ 892,079 $ 6.83
1995 activity:
Granted .................................. 752,000 1.91
Exercised ................................ (156,750) 1.04
Canceled ................................. (120,375) 1.45
---------
Balance at December 31, 1995 ................ 1,366,954 2.34
1996 activity:
Granted .................................. 1,077,875 9.32
Exercised ................................ (266,275) 3.18
Canceled ................................. (74,977) 2.58
---------
Balance at December 31, 1996 ................ 2,103,577 5.80
1997 activity:
Granted .................................. 456,194 6.62
Exercised ................................ (147,450) 1.51
Canceled ................................. (35,226) 8.60
---------
Balance at December 31, 1997 ................ 2,377,095 $ 6.19
=========
During the years ended December 31, 1997 and 1996, the Company granted
options to purchase 32,000 shares and 116,000 shares, respectively, of its
Common Stock to certain Scientific Advisory Board members in consideration for
future services. The fair value of these grants was $124,000 and $756,000,
respectively, as calculated using the Black-Scholes option pricing model.
Compensation expense is being recognized ratably over the respective vesting
period of the options. See Note 10(c) for weighted average assumptions used.
During the years ended December 31, 1997 and 1996, the Company recognized
approximately $189,000 and $95,000, respectively, in compensation expense
relating to the options granted to Scientific Advisory Board members.
During April 1995, the Company completed the sale of the remaining
one-half of its shares of capital stock of Cadus for $3.0 million to High River.
In exchange for receiving a now-expired right to repurchase all the
F-15
outstanding shares of capital stock of Cadus held by High River, the Company
granted to High River two options to purchase shares of Common Stock. One option
is for 150,000 shares at an exercise price per share equal to $2.00, subject to
adjustment under certain circumstances, and the other option is for 300,000
shares at an exercise price per share equal to $0.69, subject to adjustment
under certain circumstances. Both options will expire on April 26, 2000. The
450,000 options have a weighted average exercise price of $1.13.
On February 2, 1995, exercise prices for certain outstanding options
granted under the 1986 Plans with original exercise prices in excess of $1.25
per share were offered to be repriced to $1.25 per share, by vote of a Special
Subcommittee of the Compensation Committee of the Board of Directors. Benefit of
repricing was confined to individuals who continued to serve the Company as
employees or consultants, and 645,000 options were repriced. In connection with
the offer of repricing, the vesting schedule of those choosing to accept
repriced options was extended to June 30, 1995 for options already vested or to
vest prior to June 30, 1995. The closing trading price of the Company's Common
Stock on February 2, 1995 was $0.69.
(b) Warrants
As of December 31, 1997, a total of 2,406,145 shares of Common Stock were
issuable upon exercise of outstanding warrants. Such warrants have been issued
to certain officers, directors and other employees of the Company, certain
Scientific Advisory Board members, certain investors and certain credit
providers and investors.
A summary of warrant activity follows:
Weighted
average
exercise
Number of price per
shares share
---------- ---------
Balance at December 31, 1994 ............... 2,472,567 $ 10.01
1995 activity:
Granted ................................. 1,434,300 3.03
Exercised ............................... (15,300) 1.50
Canceled ................................ -- --
---------
Balance at December 31, 1995 ............... 3,891,567 3.15
1996 activity:
Granted ................................. 23,220 9.69
Exercised ............................... (604,892) 4.89
Canceled ................................ (34,250) 12.92
---------
Balance at December 31, 1996 ............... 3,275,645 2.41
1997 activity:
Granted ................................. 397,000 1.50
Exercised ............................... (869,500) 1.56
Canceled ................................ (397,000) 1.50
---------
Balance at December 31, 1997 ............... 2,406,145 $ 2.71
=========
In March 1997, the Company extended for a two-year period the term of an
officer's warrant to purchase 397,000 shares of the Company's Common Stock at a
per share exercise price equal to $1.50. In connection with this transaction,
the Company recognized non-cash compensation expense of approximately
$2,233,000.
During September 1996, the Company repriced certain warrants held by
investors to purchase 80,700 shares of Common Stock in order to promote their
exercise prior to pending expiration. The warrants were repriced to an amount
which was ten percent less than the average closing price for the Common Stock
for the thirty days leading
F-16
up to and including the day prior to the date of exercise. The fair market value
of the warrants was reflected as a cost of capital.
During November 1996, the Company repriced certain warrants held by
investors to purchase 130,000 shares of Common Stock in order to promote their
exercise prior to pending expiration. The warrants were repriced to an amount
which was ten percent less than the average closing price for the Common Stock
for the thirty days leading up to and including the day prior to the date of
exercise. The fair market value of the warrants was reflected as a cost of
capital.
In December 1995, the Company granted its President a ten-year warrant to
purchase 350,000 shares of Common Stock at an exercise price equal to the $5.50
trading price of the Common Stock on the date of grant. The grant of the warrant
was approved by shareholders at the Company's Annual Meeting held June 3, 1996.
On February 2, 1995, exercise prices for certain granted and outstanding
warrants were offered to be repriced to $1.50 per share. The benefit of the
repricing was confined to individuals who continued to serve the Company as
employees, directors or consultants, and 2,048,217 warrants were repriced. In
consideration for the offer of repricing, those choosing to accept the repriced
warrants were to pay the Company the difference in value before and after
repricing as calculated by use of the Black-Scholes model, which payment could
be made through promissory notes to the Company. The closing trading price of
the Company's Common Stock on February 2, 1995 was $.69.
The outstanding warrants expire and are exercisable for the number of
shares of Common Stock as shown below:
December 1999 ............................................ 47,820
March 2000 ................................................ 12,300
July 2000 ................................................. 72,000
August 2000 .............................................. 925,000
November 2000 ............................................ 12,720
March 2001 ............................................... 2,500
May 2001 ................................................. 971,805
June 2003 ................................................ 12,000
December 2005 ............................................. 350,000
---------
Total .................................................. 2,406,145
=========
(c) SFAS No. 123:
In 1996, the Company adopted the provisions of SFAS No. 123, "Accounting
for Stock Based Compensation." The following table summarizes the weighted
average fair value of stock options and warrants granted to employees and
directors during the years ended December 31, 1997 and 1996:
Option Plans
------------------------------------------------------------------------
1997 1996 1995
------------------- -------------------- -------------------
Shares $ Shares $ Shares $
------ ------- ------ ------- ------ -------
Exercise price equals market value
at date of grant .................. 424,194(1) $ 4.29 961,875(1) $ 5.56 602,000 $ 1.07
Exercise price exceeds market value
at date of grant .................. -- $ -- -- $ -- 795,000 $ 0.32
(1) Does not include 32,000 shares in 1997 and 116,000 shares in 1996
under options granted to non-employees. The fair value of these non-employee
grants has been recorded as compensation expense as prescribed under SFAS 123
and is being recognized ratably over the respective vesting period of the
options.
F-17
Warrants
------------------------------------------------------------------------
1997 1996 1995
------------------- -------------------- -------------------
Shares $ Shares $ Shares $
------ ------- ------ ------- ------ -------
Exercise price equals market value
at date of grant .................. -- $ -- 23,220 $ 5.39 1,434,300 $ 0.64
Exercise price is less than market
value at date of grant ............ 397,000(1) $ 5.91 -- $ -- -- $ --
Exercise price exceeds market value
at date of grant .................. -- $ -- -- $ -- 2,048,217 $ 0.29
(1) The only grant of warrants during 1997 was the extension of an
officer's warrant to purchase 397,000 shares of Common Stock. The extension has
been considered a cancellation of the original grant and the issuance of a new
below market grant. Accordingly, the Company recognized compensation expense
consistent with APB Opinion No. 25.
The fair value of stock options and warrants was estimated using the
Black-Scholes option pricing model. The Black-Scholes model considers a number
of variables including the exercise price and the expected life of the option,
the current price of the Common Stock, the expected volatility and the dividend
yield of the underlying Common Stock, and the risk-free interest rate during the
expected term of the option. The following summarizes the weighted average
assumptions used:
Option Plans Warrants
--------------------------------------- ----------------------------------------
1997 1996 1995 1997 1996 1995
--------- --------- --------- ---------- ---------- ---------
Expected life (years) ... 5.0 3.5 2.5 2.0 2.0 (1) 2.0
Interest rate ........... 6.00% 5.00% 5.00% 6.00% 5.00% 5.00%
Volatility .............. 72.29% 85.13% 85.13% 72.29% 85.13% 85.13%
Dividend yield .......... 0% 0% 0% 0% 0% 0%
(1) The weighted average expected life does not include the warrants repriced
in 1996 as they were exercised simultaneously.
The estimated volatility for the year ended December 31, 1997 reflects the
performance of the Company's Common Stock over the fourteen-month period ended
March 1998. The estimated volatility for the years ended December 31, 1996 and
1995 reflects the performance of the Company's Common Stock over the
twelve-month period ended December 1996. The expected life of the options and
warrants reflects the anticipated holding period prior to exercise. The
estimated risk-free interest rate used is based on risk-free investment products
with similar terms.
F-18
The following table summarizes information concerning stock options
outstanding at December 31, 1997:
Weighted
Average Weighted Weighted
Number Remaining Average Number Average
Range of Outstanding Contractual Exercise Exercisable Exercise
Exercise Prices at 12/31/97 Term Price at 12/31/97 Price
- ------------------------------ ----------- ----------- -------- ----------- --------
$0.563 - 1.063 ............... 413,625 3.61 $ 0.78 358,625 $ 0.73
1.25 - 2.00 ................. 329,625 3.42 1.60 319,125 1.61
3.75 - 5.938 ................ 189,000 8.01 5.05 124,002 5.14
6.00 ........................ 302,250 9.90 6.00 -- --
6.125 - 8.125 ............... 161,626 8.73 7.15 36,502 7.13
8.30 - 10.00 ................ 356,800 8.61 8.63 153,459 8.57
10.875 - 16.00 .............. 624,169 8.18 10.99 260,060 11.09
--------- ---------
2,377,095 7.03 6.19 1,251,773 4.69
========= =========
As of December 31, 1997, the outstanding warrants to purchase 2,406,145
common shares were all exercisable. The weighted average remaining contractual
term at December 31, 1997 for the 12,300 outstanding warrants exercisable at
$.63 per share is 2.2 years, the 24,600 exercisable at $.69 per share is 2.0
years, the 1,437,525 exercisable at $1.50 per share is 3.1 years, the 498,500
exercisable at $3.00 per share is 2.6 years, the 350,000 exercisable at $5.50
per share is 8.0 years, the 12,000 exercisable at $7.00 per share is 5.5 years,
the 23,220 exercisable at $9.69 per share is 2.0 years, the 6,000 exercisable at
$10.00 per share is 2.9 years, and the 42,000 exercisable at $13.33 per share is
3.3 years.
The Company applies APB Opinion 25 and related Interpretations in
accounting for its options and warrants. Except as previously indicated, no
compensation cost has been recognized for its stock option and warrant grants.
Had compensation cost for the Company's stock option grants been determined
based on the fair value at the grant dates for awards consistent with the method
of SFAS No. 123, the Company's net loss and loss per share would have been
increased to the pro forma amounts indicated below.
Year Ended December 31,
--------------------------------------------
1997 1996 1995
----------- ------------- -------------
Net loss to common stockholders As reported $(15,654,000) $ (16,015,000) $ (9,641,000)
Pro forma (13,511,000) (19,653,000) (11,728,000)
Loss per share Basic and diluted:
As reported (0.67) (0.83) (0.72)
Pro forma (0.58) (1.01) (0.88)
The pro forma effect on the loss for the years ended December 31, 1997,
1996, and 1995 is not necessarily indicative of the pro forma effect on future
years operating results since it does not take into effect the pro forma
compensation expense related to grants made prior to January 1, 1995.
F-19
(11) Income Taxes
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at December 31,
1997 and December 31, 1996 are presented below.
December 31, December 31,
1997 1996
------------ ------------
Deferred tax assets:
Liability to reacquire IL-6m
rights and materials .................. $ 262,000 $ 863,000
Research and development
credit carryforward ................... 2,303,000 1,883,000
Compensation relating to the
issuance of stock options
and warrants .......................... 189,000 2,740,000
Net operating loss carryforwards ........ 52,408,000 44,374,000
Other ................................... 1,116,000 958,000
------------ ------------
Total gross deferred tax assets ............ 56,278,000 50,818,000
Less valuation allowance ................ (56,278,000) (50,818,000)
------------ ------------
Net deferred tax assets ................. -- --
------------ ------------
Deferred tax liabilities:
Total gross deferred tax
liabilities ........................... -- --
------------ ------------
Net deferred tax ........................ $ -- $ --
============ ============
At December 31, 1997, the Company had net operating loss carryforwards for
federal income tax purposes of approximately $115,000,000 which expire at
various dates from 2000 through 2012. At December 31, 1997, the Company had
research credit carryforwards of approximately $2,303,000 which expire at
various dates between years 2001 and 2012. Pursuant to Section 382 of the
Internal Revenue Code of 1986, as amended, the annual utilization of the
Company's net operating loss and research credit carryforwards may be limited if
the Company experiences a change in ownership of more than 50 percentage points
within a three-year period. Since 1986, the Company experienced two ownership
changes. Accordingly, the Company is significantly limited in utilizing its tax
net operating loss carryforwards arising before such ownership changes to offset
future federal taxable income. Similarly, the Company is significantly
restricted in using its research credit carryforwards arising before such
ownership changes to offset future federal income tax expense.
(12) Commitments
Leases
The Company leases premises under an operating lease, a portion of which
expired in 1993 and a portion of which expires in 1999. The Company has extended
the 1993 expired portion of the lease through 1997 at 85% of each year's fair
market rental value and from 1997 to 1999 at 100% of each year's fair market
rental value, for a portion of the premises. The rate for the remaining portion
of the premises is $264,000 annually through March 31, 1997 and $285,000
annually through March 31, 1999. Rent expense for leased premises was
approximately $554,000, $508,000, and $493,000 for the years ended December 31,
1997, 1996 and 1995, respectively. See also Note 7.
F-20
Future minimum lease payments under the capital and operating leases are
as follows:
Capital Operating
Years ending December 31, Leases Leases
----------- -----------
1998 .................................... $ 510,000 $ 564,000
1999 .................................... 559,000 323,000
2000 .................................... 505,000 9,000
2001 .................................... 143,000 1,000
2002 .................................... 3,000 --
----------- -----------
1,720,000 897,000
Less interest expense .................... (251,000) --
----------- -----------
$ 1,469,000 $ 897,000
=========== ===========
Supported Research
The Company has entered into various research and license agreements with
certain academic institutions and others to supplement the Company's research
activities and to obtain for the Company rights to certain technology. The
agreements generally require the Company to fund the research and to pay
royalties based upon percentages of revenues, if any, on sales of products
developed from technology arising under these agreements.
Consulting Agreements
The Company has consulting agreements with several of its Scientific
Advisory Board members and other consultants. These agreements generally are for
a term of one year or are terminable at the Company's option.
(13) Retirement Plans
The Company maintains a 401(k) retirement plan available to all full-time,
eligible employees. Employee contributions are voluntary and are determined on
an individual basis, limited to the maximum amount allowable under federal tax
regulations. The Company, at its discretion, may make certain contributions to
the plan. No such contributions have been made to the plan during the years
ended December 31, 1997, 1996 and 1995.
(14) Supplemental Cash Flow Information and Non-cash Investing and Financing
Activities are as follows:
Year Ended December 31,
--------------------------------
1997 1996 1995
---------- --------- --------
Cash paid during the year for:
Interest ................................. $ 707,000 $ 817,000 $504,000
========= ========= ========
Non-cash investing and finance
activities:
Finova capital asset and lease
obligations additions ................... 1,324,000 421,000 --
========= ========= ========
Fair value of Finova warrant .............. -- 125,000 --
========= ========= ========
Other capital lease obligations ........... 28,000 -- --
========= ========= ========
Unrealized gain (loss) on securities
available-for-sale ...................... 101,000 (49,000) --
========= ========= ========
Extinguishment of Oracle Group
debt for stock .......................... -- 2,500,000 --
========= ========= ========
Extinguishment of director
debt for stock .......................... -- 180,000 --
========= ========= ========
Preferred Stock dividend .................. 163,000 -- --
========= ========= ========
F-21
(15) Related Party Transactions
Through March 1995, the Company made miscellaneous noninterest-bearing
cash advances to the President and CEO of the Company totaling approximately
$156,000. The officer provided the Company with a demand promissory note
pursuant to which the officer was obligated to repay the debt over a twenty-four
month period ending April 30, 1997. In March 1997, the Company accepted a new
promissory note (the "new promissory note") in the aggregate amount of $110,000
from the officer. The new promissory note was payable as to $15,000 no later
than May 15, 1997 and the remainder upon the earlier of on demand by the Company
or December 31, 1997 and bore interest at the rate of 5% compounded quarterly.
The new promissory note covered the remaining balance of the original note,
interest thereon and additional miscellaneous cash advances made since the date
of the original note totaling $15,000. At December 31, 1997, the new promissory
note was paid in full by the officer.
In January 1996, the Company paid Concord International Investment Group,
LP, approximately $163,000 for services rendered by it to the Company in
connection with structuring a contemplated product related financing for C225.
Mr. Robert F. Goldhammer, Chairman of the Board of Directors, is a limited
partner of Concord International Investment Group, LP.
In August 1995 and January 1996, the Company paid Delano & Kopperl
Financial Advisors, Inc. a total of approximately $69,000 for services rendered
by it to the Company in connection with structuring a contemplated product
related financing for C225. Paul B. Kopperl, a director of the Company, is
President, director, and 25% shareholder of Delano & Kopperl Financial Advisors,
Inc.
In January 1998, the Company accepted a promissory note totaling
approximately $131,000 from its President and CEO in connection with the
exercise of a warrant to purchase 87,305 shares of the Company's Common Stock.
The note is due no later than two years from issuance and bears annual interest
at the rate of 8.5%.
(16) Fair Value of Financial Instruments
For the years ended December 31, 1997 and 1996, the following methods and
assumptions were used to estimate the fair value of each class of financial
instrument:
Cash and cash equivalents, accounts payable, accrued and other current
liabilities
The carrying amounts approximate fair value because of the short maturity
of those instruments.
Long-term debt
Discounted cash flow analyses were used to determine the fair value of
long-term debt because quoted market prices on these instruments were
unavailable. The fair value of these instruments approximated the carrying
amount.
F-22
(17) Summary of Quarterly Results of Operations (Unaudited)
The following unaudited quarterly financial information includes, in
management's opinion, all normal and recurring adjustments necessary to fairly
present the Company's results of operations and related information for the
periods presented.
Quarter Ended
---------------------------------------------------------
March 31 June 30 September 30 December 31
------------ ----------- ------------ -----------
Year ended December 31, 1997:
Revenues ................................. $ 75,000 $ 3,196,000 $ 742,000 $ 1,335,000
Operating expenses ....................... 6,478,000 4,529,000 4,359,000 6,445,000
----------- ----------- ----------- ----------
Operating loss ........................... (6,403,000) (1,333,000) (3,617,000) (5,110,000)
Net interest and other income ............ (50,000) (295,000) (283,000) (344,000)
----------- ----------- ----------- ----------
Net loss ................................. (6,353,000) (1,038,000) (3,334,000) (4,766,000)
Preferred stock dividends
(including incremental
yield of $51,000) ..................... -- -- -- 163,000
----------- ----------- ----------- ----------
Net loss to common stockholders .......... $(6,353,000) $(1,038,000) $(3,334,000) $(4,929,000)
=========== =========== =========== ===========
Basic and diluted net loss
per common share ....................... $ (0.30) $ (0.04) $ (0.14) $ (0.20)
=========== =========== =========== ===========
Year ended December 31, 1996:
Revenues ................................. $ 75,000 $ 75,000 $ 75,000 $ 375,000
Operating expenses ....................... 3,066,000 3,438,000 3,714,000 5,225,000
----------- ----------- ----------- ----------
Operating loss ........................... (2,991,000) (3,363,000) (3,639,000) (4,850,000)
Net interest and other expense
(income) ............................... 154,000 (61,000) (97,000) (91,000)
----------- ----------- ----------- ----------
Loss before extraordinary item ........... (3,145,000) (3,302,000) (3,542,000) (4,759,000)
Extraordinary loss on
extinguishment of debt ................. -- 1,267,000 -- --
----------- ----------- ----------- ----------
Net loss ................................. $(3,145,000) $(4,569,000) $(3,542,000) $(4,759,000)
=========== =========== =========== ===========
Basic and diluted net loss per
common share:
Loss before extraordinary item ........... $ (0.18) $ (0.17) $ (0.18) $ (0.24)
Extraordinary loss on extinguishment
of debt ................................ -- 0.06 -- --
----------- ----------- ----------- ----------
Net loss per common share ................ $ (0.18) $ (0.23) $ (0.18) $ (0.24)
=========== =========== =========== ===========
F-23